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1.1 Cancer statistics 
Cancer is one of the major burdens of the 21st century, both in economically 
developed and less developed countries.  
As estimated in the GLOBOCAN series of the International Agency for 
Research on Cancer, the worldwide incidence and mortality for all cancers 
increased to 14.1 million new-diagnosed cases and 8.2 million cancer-related 
deaths in 2012 (Ferlay et al, 2015).  
When age-standardized rate as a weighted mean of the age-specific rates is 
taken as a basis, the most common types in men remain lung, prostate and 
colorectal cancer, respectively breast, colorectal and cervical carcinoma in 
women (Torre et al, 2015). Worldwide, most cancer patients die from lung, liver 
or stomach cancer (Ferlay et al, 2015).  
In developed regions, however, colorectal cancer is the second leading cause 
of cancer-related death in men, respectively the third in women (Torre et al, 
2015). Malignant neoplasia are number two following heart disease as cause of 
death in the United States (Siegel et al, 2016).  
Looking worldwide, cancer is responsible for even more deaths than coronary 








Figure 1. Worldwide estimated age-standardized incidence and mortality rates for both 
sexes in 2012, taken from Ferlay et al. (Ferlay et al, 2013) 
The unrestricted use of this figure is granted by the publisher.  
1.2 Selected tumor entities and therapeutic options so far 
In this thesis, we focused on three tumor entities, i.e., colorectal carcinoma, 
renal cell carcinoma and soft tissue sarcoma. As specified in section 1.4, cell 
lines of these origins were selected because of their assured high-grade 
resistance towards oncolytic virotherapy. Moreover, it is of great importance to 
analyze these cancer types in detail because of their world frequency and quite 
limited treatment options. 
 Colorectal cancer 
Colorectal cancer (CRC), as one of the most common types in both sexes, is 
diagnosed in localized stages only in 39 % of the cases (Siegel et al, 2017). 
Due to the use of CRC screening, however, precursor lesions and CRC are 
detected earlier and in some cases exclusive endoscopic resection is sufficient 




(von Karsa et al, 2013). In localized stage, surgery is the favored treatment 
option for CRC, provided that resection with adequate margins and lymphaden-
ectomy is feasible (Cunningham et al, 2010). For invasive rectal cancer, the 
total excision of the mesorectum is indispensable (Quirke et al, 2009). 
Combinatorial approaches with chemotherapy and radiation treatment are 
common practice in rectal cancer (Cunningham et al, 2010), since chemo-
radiation provides a lower incidence of local recurrence (Bosset et al, 2006). For 
colon cancer, the recommendation of adjuvant chemotherapy depends on the 
lymph node status. The application of targeted drugs in early stage disease is 
also discussed with caution, since bevacizumab and cetuximab (monoclonal 
antibodies against vascular endothelial factor (VEGF), respectively against 
epidermal growth factor receptor (EGFR)) seem to have no or only small effect 
on survival rates for this subgroup, but do include severe side-effects 
(Cunningham et al, 2010).  
Fortunately, CRC diagnosed as oligometastatic but resectable disease is no 
longer a death sentence (Cunningham et al, 2010; Jones et al, 2014). Even for 
patients suffering from unresectable metastatic disease, combinatorial 
treatment containing targeted therapy and multiple cytotoxic agents has 
increased overall survival to more than 30 months (Fakih, 2015; Kasi et al, 
2015). Nevertheless, for most patients with stage IV disease, CRC remains 
incurable. Thus, the 5-year survival rate decelerates to 14 % when patients are 
diagnosed at distant stages (Siegel et al, 2017).  
 Kidney cancer 
Kidney cancer is ranked the ninth most common cancer type in men, 
respectively the fourteenth in women (Ferlay et al, 2013). Although improved 
relative survival rates have been reported recently, the incidence of renal cell 
carcinoma has increased (Capitanio & Montorsi, 2016).  
Moreover, masses are often diagnosed in advanced or metastatic stages 
(Siegel et al, 2016). Due to robot-assisted or laparoscopic nephron-sparing 





care) can be prevented in most cases of local-stage disease (Sun et al, 2012). 
Renal cell carcinoma has been considered both chemo- and radioresistant for 
quite a long time. However, radiotherapy (RT) offers adjuvant treatment options 
in selected patients and palliative low-dose RT improves pain level and cancer-
related symptoms in unresectable metastatic disease (Dengina et al, 2017). 
With limited success and severe side effects, those patients were formerly 
treated with immunomodulatory drugs like interferon α and interleukin-2. Today, 
targeted therapies affecting mainly VEGF, PDGFR and mTOR pathways reduce 
toxic effects and convince with sustainable response rates in this subgroup 
(Capitanio & Montorsi, 2016). Nevertheless, an ongoing, complete remission 
remains the great exception.  
 Sarcomas 
Soft-tissue and bone sarcomas, which are tumors of mesenchymal cell origin, 
play a minor role in adults, but following leukemia and cancers of the brain and 
nervous system, sarcomas are the third most common cancer type in children 
(Siegel et al, 2016). In this age group, soft-tissue sarcomas occur more 
frequently with rhabdomyosarcoma as the most common histologic subtype 
(von Mehren et al, 2016).  
Dependent on the affected region of the body, cancer stage and tumor histology 
treatment options diverge. Surgical resection as standard of care is usually 
accompanied by pre- or postoperative radiation and/or chemotherapy (von 
Mehren et al, 2016). In advanced metastatic stage and unresectable disease, 
the application of the chemotherapeutic agent doxorubicin alone or in 
combination with ifosfamide has been first-line therapy for more than three 
decades (Skafida et al, 2017). Nevertheless, other chemotherapeutic treatment 
regimen showed promising results (von Mehren et al, 2016). Recently, 
pazopanib, a receptor tyrosine kinase inhibitor, has been recommended for the 
application in palliative situations (von Mehren et al, 2016). However, with a 
median overall survival of 14–17 months, the outcome of patients with 
metastatic disease is unacceptable (Frezza et al, 2017).  




Summing up, there are three major treatment options to defeat various types of 
cancer: Surgery, chemotherapy and radiation treatment. Additionally, a plenti-
tude of innovative therapeutics is offered including, i.e., hormone-therapy, 
targeted therapy using small molecules or monoclonal antibodies and immuno-
therapy.  
However, all of these treatment options offer limited success for any number of 
reasons. On the one hand, therapeutic options and response rates are 
dependent on cancer type, stage and subgroup analysis. On the other hand, 
cancerous cells behave heterogeneously: they evolve continuously and may 
have acquired drug resistance and additional features during the time of first-
line treatment (Bell, 2007; Melcher et al, 2011). Furthermore, each therapy 
implies severe side-effects and may be therefore not appropriate for each 
patient to the same extent.  
Especially in metastatic stage disease, a complete remission and cure of cancer 
is most rare (Melcher et al, 2011; Ottolino-Perry et al, 2010). Thus, novel 
therapeutic approaches, which are established with the knowledge of the need 
of individualized medicine, are desperately required. 
1.3 Oncolytic virotherapy  
Oncolytic viruses (OVs) have an inherent potential to destroy cancer cells 
without causing damage to normal tissue (Russell & Peng, 2007; Russell et al, 
2012). OVs are live, self-replicating agents that can be attenuated for safety 
concerns and genetically armed to improve their anticancer efficacy (Bell, 
2007). Until now, the molecular and cellular mechanisms of tumor cell killing are 
not completely elucidated, but selective, direct tumor cell lysis and the 
subsequent occurrence of systemic antitumor immunity seem to be of prime 
importance (Kaufman et al, 2015).  
 Historical overview 
Described first in the early 20th century, oncolytic virotherapy has been 





cancer therapeutics, however, happened by accident. Cases of cancer patients, 
who experienced clinical remission after contagion with an infectious disease, 
were reported since the turn of the 19th century (DePace, 1912; Dock, 1904; 
Kelly & Russell, 2007). While the discovery of viruses and their function as 
triggers of infectious diseases was at its very beginning, occasional case 
reports of cancer patients in remission provided us with another perspective. In 
some cases the observed tumor regress was associated with a coincidental 
infection of known viral etiology, e.g., a contagion with wildtype measles virus 
(Bluming & Ziegler, 1971; Pasquinucci, 1971; Taqi et al, 1981; Zygiert, 1971). 
Even though remissions were short-lasting and incomplete, first clinical trials, 
promoting viruses as novel anticancer agents, were executed shortly after 
(Bierman et al, 1953; Hoster et al, 1949; Southam & Moore, 1952).  
Although temporary cancer regress in patients suffering from 
immunosuppressive malignancies had been demonstrated, arising virus 
infection of normal tissue became an unacceptable side-effect (Cattaneo et al, 
2008; Kelly & Russell, 2007). In the 1950s and 1960s, after enhanced cell 
culture techniques and rodent models had been established, oncolytic viruses 
were characterized enthusiastically (Alemany, 2013; Kelly & Russell, 2007). 
However, once these viruses were applied to immunocompetent animals and 
men, the previously observed regress was no longer convincingly reproducible 
(Moore, 1954; Southam & Moore, 1952). The host´s immune response against 
the virus was traded as prime suspect, and, as a consequence, virus 
oncotherapy was almost abandoned in the 1970s (Alemany, 2013).  
Later on, the unintentional immune rejection turned out to be a “double-edged 
sword”: in preclinical (Boone et al, 1971; Kaji et al, 1969; Lindenmann & Klein, 
1967) and clinical (Asada, 1974) trials researchers were able to detect a 
sustainable antitumor immunity after application of OVs (Alemany, 2013; 
Melcher et al, 2011). Subsequently, the concept of viruses as 
immunotherapeutic agents attracted interest. Although attempts had been made 
to induce specific tropism by successive passage of oncolytic viruses in cultured 
cancer cells (Moore, 1952), the third and enduring phase of research oncolytic 
virotherapy started only two decades ago, when genetically engineered OVs 




have become available (Alemany, 2013; Cattaneo et al, 2008; Kelly & Russell, 
2007).  
Referring to the current state of research, clinical trials seem to overcome 
previous hurdles. In 2005, world´s first oncolytic agent, the modified adenovirus 
H101, was accredited for cancer treatment by the Chinese regulatory authorities 
(Garber, 2006; Jiang et al, 2006). Currently, talimogene laherparepvec (T-VEC), 
a modified herpes simplex virus encoding granulocyte-macrophage colony-
stimulating factor, was approved by the US Food and Drug Administration and 
the European Commission as “first-of-its-kind” cancer treatment of melanoma 
(Andtbacka et al, 2015; Ledford, 2015; Zhang, 2015). By overcoming remaining 
obstacles, oncolytic virotherapy shall become the long-awaited cure of 
metastatic cancer. 
 Mechanisms of tumor cell destruction 
Oncolytic viruses do selectively infect, replicate within and lyse tumor cells, 
while attack of normal tissue occurs only to a limited extent (Kaufman et al, 
2015; Russell et al, 2012). Cancer cell specific cell entry followed by viral 
replication, initiation of cell death programs and cell lysis are indispensable 
components of direct tumor cell killing. Some OVs, like herpes simplex and 
measles virus, infiltrate cells by docking to specific receptors, which are 
fortunately overexpressed on cancer cells (Alemany, 2013; Kaufman et al, 
2015). Others, like vaccinia virus, enter host cells by endocytic process 
(Kaufman et al, 2015).  
Effective antiviral response mechanisms, based most frequently on the 
inhibition of protein translation, will be executed, if a normal cell experiences 
viral entry (Alemany, 2013; Kaufman et al, 2015). Thus, so called Toll-like-
receptors, which are activated by local interferon (IFN) release or triggered by 
viral fragments, stimulate several downstream pathways for the induction of 
apoptosis and viral clearance (Elde et al, 2009; Kaufman et al, 2015).  
In cancer cells, however, cell cycle regulating pathways are often defective 





of the antiviral IFN pathway, the EGFR cascade, the protein kinase B, protein 
kinase R or human rat sarcoma (RAS) family (Bell, 2007; Kaufman et al, 2015). 
Thereby, abnormal cells are enabled to avoid immune detection and to resist 
apoptosis (Bell, 2007; Kaufman et al, 2015; Russell et al, 2012). Fortunately, 
mutations in cell cycle regulating pathways offer specific tropisms to oncolytic 
viruses. Vaccinia virus, for example, is most reliant on RAS signaling, which is 
induced by the activation of EGFR (Parato et al, 2012). Accordingly, poxviruses 
show a natural selectivity for EGFR-overexpressing cancer cells (Kaufman et al, 
2015). 
 
Although being a “double-edged sword”, the emerging immune response after 
oncolytic virus treatment plays another leading role in oncolytic virotherapy - 
perhaps it is the more important one (Alemany, 2013; Russell et al, 2012). 
Coming along with direct tumor cell killing, oncolytic viruses are able to induce a 
strong and sustainable anticancer immunity by release of tumor-associated 
antigens (TAA), death signals (cellular proteins that stimulate the host immune 
system) and neo-antigens (new, cancer-specific antigens) (Kaufman et al, 
2015). The host anticancer immune reaction consists of systemic innate and 
tumor-specific adaptive immune response. Antigen-presenting cells process 
TAA and neo-antigens, represent those fragments on their cell surface and, 
thereby, activate antigen-specific CD4+ and CD8+ T cells (Kaufman et al, 2015). 
CD8+ T cells and natural killer cells, which are either stimulated by 
downregulated major histocompatibility complex (MHC) class I expression or by 
type I IFN, identify and subsequently eliminate the tumor cells (Zamarin et al, 
2014). Thus, targeting the host immune response to cancer cells may lead to 
tumor regression even at distant, uninfected tumor sites (Kaufman et al, 2015; 
Russell et al, 2012). 
 





Figure 2. Mechanisms of tumor cell destruction  
 
Summing up, oncolytic virotherapy is a promising new approach in cancer 
treatment due to two distinct mechanisms of action: direct tumor cell killing and 
the subsequent occurrence of anticancer immune response (Kaufman et al, 
2015). 
So far, numerous DNA and RNA viruses have demonstrated their ability to act 
as such anticancer agents. To name only a few, recombinant adenovirus (Ad) 
(Jiang et al, 2006), recombinant herpesvirus (Andtbacka et al, 2015), human 
reovirus (Norman & Lee, 2000), recombinant enteroviruses (Yla-Pelto et al, 
2016), Newcastle disease virus (NDV) (Cassel & Murray, 1992), vesicular 
stomatitis virus (VSV) (Hastie & Grdzelishvili, 2012), recombinant vaccinia virus 
(VACV) (Kirn & Thorne, 2009) and attenuated measles virus (MeV) (Russell & 
Peng, 2009) have revealed convincing oncolytic potential in several preclinical 






 Obstacles and limitations 
Despite all advantages of oncolytic virotherapy, obstacles to a successful 
application in immunocompetent men have come into focus in the last decades. 
Thus, premature viral clearance due to preexisting or quickly generated anti-
bodies and activated T lymphocytes constitutes a problem (Chiocca & Rabkin, 
2014; Kaufman et al, 2015). Secondly, evidence has grown that oncolytic 
viruses are also blocked by haemagglutination and components of the 
complement system (Kaufman et al, 2015; Magge et al, 2013; Tesfay et al, 
2014). Additionally, tumors pursue intelligent strategies to evade immune 
detection: by recruiting tumor-promoting immune cells and expression of 
immune-inhibitory surface molecules, cancer cells create an immuno-
suppressive tumor microenvironment in order to protect the tumor and promote 
malignant degeneration (Hanahan & Weinberg, 2011; Kaufman et al, 2015). 
Furthermore, virus delivery is halted by sequestration of virions in liver and 
spleen, procured by the mononuclear phagocytic system, as well as by poor 
extravasation of viral agents from tumor blood vessels (Russell et al, 2012). In 
addition, physical barriers like hypoxia, acidosis, calcification and high interstitial 
pressure - conditions that characterize tumor microenvironments - limit oncolytic 
virus efficacy (Kaufman et al, 2015). Finally, extracellular matrix proteins and 
cancer-associated fibroblasts, although non-permissive to viral replication, 
reduce the delivery of viral progeny (Alemany, 2013; Kaufman et al, 2015; 
Lopez et al, 2009).  
Besides the manifold challenges of virus delivery, the lack of selective cancer 
cell tropism is a hurdle that needs to be conquered both for improved anticancer 
efficacy and better safety of oncolytic agents (Rudin et al, 2011). However, the 
attenuation of oncolytic viruses for safety concerns includes quite often the 
limitation of their oncolytic potential (Kelly & Russell, 2007; Russell et al, 2012). 
OVs, as self-replicating agents, are able to multiply independent of the applied 
dose. On the one hand, this constitutes a certain benefit, since small doses of 
viral particles can achieve a clinical effect (Kaufman et al, 2015). On the other 




hand, tumor lysis syndrome and massive cytokine release in answer to a 
successful virus replication may represent the second side of the coin 
(Alemany, 2013). Another safety topic addresses the theoretical concern of 
virus evolution: Genetically attenuated oncolytic agents could regain their wild 
type pathogenicity, which would lead to a safety problem not only for patient but 
for contacts (Russell et al, 2012). In addition, the risk of virus integration into the 
host genome provides ground for discussion (Kaufman et al, 2015).  
As detailed in section 1.3.2, the partial inhibition of antiviral mechanisms in most 
cancers make tumor cells an ideal breeding ground for oncolytic viruses. 
Nevertheless, maintained antiviral activity can lead to a limited sensitivity or 
even resistance to oncolytic viruses (Russell et al, 2012).  
Accordingly, the ideal oncolytic virus needs to combine an outstanding safety 
profile with convincing antitumor mechanisms - mediated through direct tumor 
cell killing and subsequent induction of anticancer immune response. The viral 
agent needs to be successfully delivered by systemic application and should be 
able to reach all kinds and states of tumor cells. 
 Approaches to overcome limitations 
Since the first promising attempt in 1991, the concept of an ideal oncolytic virus 
has been further promoted by the application of three principles of genetic 
engineering, referred to as shielding, targeting and arming (Martuza et al, 
1991). Moreover, oncolytic viruses have been combined with well-established 
therapies like chemotherapy, radiation treatment and immunotherapy for quite a 
while (Cattaneo et al, 2008; Kaufman et al, 2015; Ottolino-Perry et al, 2010). A 
novel therapeutic approach, as executed in this thesis for oncolytic vaccinia and 
measles vaccine virus, is pursued by combinatorial treatment using two distinct 
oncolytic virus constructs.  
1.3.4.1 Combination of oncolytic viruses 
In order to overcome partial resistance of cancer cells towards oncolytic 





represents a sustainable approach. Although the idea of gaining a benefit from 
synergistic interactions has been pursued by combination therapies before, 
here, the innovative character is due to the fact that both viral agents can be 
genetically engineered to compensate each other´s malfunctions (Le Boeuf et 
al, 2010; Tysome et al, 2012). Furthermore, oncolytic viruses are able to 
destroy cancer cells in more than one way: they induce apoptosis as well as 
necrosis or pyroptosis in infected cells (Kaufman et al, 2015). These multitude 
forms of induced cell death may provide an advantage over the key-and-lock 
principle of a combination of oncolytic viruses with highly acclaimed targeted 
therapy (Le Boeuf et al, 2010). 
In 1991, Japanese researchers demonstrated a first coinfection of swine 
testicular cells by Hog Cholera Virus and NDV (Kumagai et al, 1961). Some 
years later, Tsuchiya and Tagaya reported on viral superinfection of Yaba virus-
infected cells (Tsuchiya & Tagaya, 1970), and the improved ability of an 
enterovirus to form plaques after pretreatment with poxviruses (Tsuchiya & 
Tagaya, 1972a; Tsuchiya & Tagaya, 1972b). Tysome et al. presented a 
sequential combination applying wildtype adenovirus (Ad5) and the attenuated 
Lister vaccine strain of vaccinia virus (VVLister) in an immunocompetent Syrian 
hamster model (Tysome et al, 2012). An intratumoral administration of three 
doses of Ad5 followed by three doses of VVLister eradicated the sub-
cutaneously established pancreatic, respectively kidney, Syrian hamster tumor 
cell lines (Tysome et al, 2012). Le Boeuf et al., who combined a vaccinia virus 
(VV) and a VSV strain, explained their decision to apply VV as a DNA-based 
virus and VSV as RNA-based component as follows (Le Boeuf et al, 2010). 
Firstly, the risk of virus evolution was effectively prohibited because replication 
cycles take place at different locations inside the cell (Le Boeuf et al, 2010). 
Secondly, in contrast to one “supervirus” with an unpredictable risk of infection 
of normal tissue, both attenuated viruses convinced with outstanding safety 
profiles (Le Boeuf et al, 2010). Thirdly, two immunologically distinct agents 
might have increased the chance to circumvent the antiviral immune response, 
thus, offering possibilities for multiple virus injections. Furthermore, DNA-viruses 
offer great packing capacities for additional transgenes. In return, the smaller 




RNA-viruses do quickly replicate, which enables them to escape the adaptive 
immune response (Le Boeuf et al, 2010). 
In detail, Le Boeuf et al. chose a double-deleted VV-version (VVDD), which is 
contingent upon functional EGFR pathways in E2F-overexpressing cancer cells 
(Le Boeuf et al, 2010). VVDD encodes B18R, a soluble type I IFN receptor, 
which blocks the emerging cellular antiviral response (Le Boeuf et al, 2010). 
Fittingly, the utilized recombinant version of VSV (VSVΔ51) is most sensitive to 
IFN, which hinders viral replication in normal cells but retargets this virus to 
cancer cells with a reduced IFN release (Le Boeuf et al, 2010). In the course of 
the work, Le Boeuf et al. equipped VSVΔ51 with p14FAST, a gene product that 
supports VV spreading by induction of cell fusion (Le Boeuf et al, 2010). Thus, 
two supportively acting virus platforms had been generated and provided a 
great example of how attenuation of oncolytic agents can go hand in hand with 
enhanced oncolytic potential. VVDD and VSVΔ51 got genetically armed to 
express fluorescent proteins (VVDD with eGFP, VSVΔ51 with DsRed) in order 
to observe viral infection and spreading within the infected cell culture (Le Boeuf 
et al, 2010). As observed under fluorescence microscope, the majority of 
double-treated cells was not coinfected, instead, the initial infection by VVDD 
sensitized neighboring cells for the following VSVΔ51 treatment (Le Boeuf et al, 
2010). Le Boeuf et al. investigated their coinfection model in vitro, both in 
immunodeficient and –competent murine tumor models, and, ex vivo, on human 
cancer samples (Le Boeuf et al, 2010). The researchers were able to 
demonstrate that “synergistic interaction between oncolytic viruses augments 
tumor killing” (Le Boeuf et al, 2010).  
1.4 Selected oncolytic virus platforms and human cancer cell lines of this thesis  
 Measles virus  
The measles virus, first isolated from 11-year old David Edmonston by Enders 
and Peebles in 1954, belongs to the family of Paramyxoviridae (Enders & 
Peebles, 1954). Ranging in size from 100-300 nm (Griffin, 2001), the virion is 





glycoproteins H (haemagglutinin) and F (fusion glycoprotein), and the M- (matrix 
protein) protein that connects the inner leaflet with the ribonucleoprotein (RNP) 
complex. This nucleocapsid consists of nucleoprotein (N), phosphoprotein (P), 
large protein (L) and the negative single-stranded RNA. The measles virus 
genome also encodes for the nonstructural proteins V and C (Griffin, 2001; 
Lamb & Kolakofsky, 2001).  
Naturally, host cell entry begins with viral H-protein binding the cellular receptor 
SLAM, which subsequently enables F-protein to initiate membrane fusion 
(Griffin, 2001; Yanagi et al, 2006). While laboratory propagation, wild-type 
measles virus was forced to adapt to many different human and animal cells 
lacking SLAM. Resulting, mutants became accustomed to enter host cells via 
CD46 and nectin-4 (Dorig et al, 1993; Naniche et al, 1993; Noyce et al, 2011). 
Interestingly, whereas normal cells exhibit only low CD46 receptor densities, 
many cancer cells overexpress CD46 as possible safeguard mechanism to 
avoid complement-mediated lysis (Anderson et al, 2004; Fishelson et al, 2003). 
Transcription and all further steps of viral replication take place in the cytoplasm 
and are coordinated by P-, N- and L-protein. The N-gene is transcribed most 
frequently because of its upstream position in the genome. This fact is of some 
importance as it advocates where to place transgenes, for example light-
emitting GFP, the best. A sufficient production of negative single-stranded 
RNAs ends the replication cycle and newly assembled viral progeny begin to 
spread. Even though the mechanism of virus release is not completely under-
stood, in polarized epithelial cells close contact of the M-protein to the RNP 
complex seems to be important (Lamb & Kolakofsky, 2001; Nakatsu et al, 
2013). Syncytia formation, a different cell shape and the appearance of 
inclusion bodies inside infected cells herald the oncoming cell death (Griffin, 
2001).  




                    
Figure 3. Schematic structure of MeV 
The measles virus is built up of a phospholipid bilayer envelope (dark grey), which contains the 
transmembrane glycoproteins haemagglutinin (H) and fusion (F), and connects to the matrix 
protein (M). The M-protein surrounds the negative single-stranded RNA (not shown) that is 
associated with the nucleoprotein (N), the phosphoprotein (P) and the large protein (L). 
 
Wild-type measles virus can lead to severe complications especially when 
immunosuppressed individuals are infected (Griffin et al, 2008; Schneider-
Schaulies & ter Meulen, 2002). Attenuated strains, however, convince with 
similar oncolytic activity while side effects of infection are reduced to flu-like 
symptoms. The first live attenuated measles vaccine strain, the Edmonston-B-
strain, was generated by inoculation of wild-type Edmonston strain to chick 
embryos (Griffin, 2001). Since 1965, the Schwarz vaccine, a further 
development of the Edmonston B strain, has been traded as standard measles 
vaccine in most countries of the world. Until now, more than a billion people 
have been immunized (Griffin, 2001). Except for recipients with extremely 
compromised immune system, these attenuated virus strains are safe products 
and suitable for children from 9 months on (Griffin, 2001; Griffin et al, 2008).  
In comparison to wild-type MeV, reduced pathogenicity of attenuated versions is 
achieved by receptor targeting (Russell & Peng, 2009) and mutation of viral 
nonstructural proteins. Thus, point mutations in the gene encoding nonstructural 
protein V lead to a reduced suppression of type I interferon upon inoculation 
with measles vaccine viruses (Ohno et al, 2004; Takaki et al, 2011). In cells with 





cancer cells, however, defects of cell cycle regulating pathways lead to 
unhindered virus infection and replication of these mutants.  
In this thesis we applied MeV-GFP, a vector derived from the Edmonston-B-




Figure 4. MeV-derived reporter gene vector MeV-GFP, provided by the courtesy of Prof. 
Dr. Ulrich M. Lauer 
The blue arrow encodes green fluorescent protein (GFP). 
 
 Vaccinia virus  
Vaccinia virus belongs to the Poxvirus family and is a member of the Orthopox-
virus genus. With a diameter of 260-380 nm and a genome capacity of 190 kbp 
encoding approximately 250 genes, it represents the largest virus we know 
(Malkin et al, 2003; Moss & Earl, 2001). During replication, the double-stranded 
DNA virus exists in four different forms: the intracellular mature virion (IMV), the 
intracellular enveloped virion (IEV), the cell-associated enveloped virion (CEV) 
and the extracellular enveloped virion (EEV) (Schmidt et al, 2012; Smith et al, 
2002). The mature virion is built up of the viral core, which contains the s-
shaped double-stranded DNA genome, viral enzymes and proteins, two lateral 
bodies with unknown function, and a phospholipid bilayer with approximately 25 
viral surface proteins incorporated (Moss, 2007; Schmidt et al, 2012). The 
vaccinia virus has the ability to invade lots of different cell types by endocytosis, 
however, detailed information about host cell entry remains nebulous (Harrison 
et al, 2004; Schmidt et al, 2012). Immediately after delivery of the core into the 
cytoplasm, early viral mRNAs are transcribed (Schramm & Locker, 2005). The 
translated gene products are essential for the following viral replication 
(Schramm & Locker, 2005), intermediate gene expression and suppression of 
an emerging cellular immune response (Moore & Smith, 1992; Thorne et al, 




2005). Among DNA viruses, poxviruses are unique because they replicate 
preferentially in the cytoplasm. To replicate almost independently of the cellular 
replication machinery, VACV brings its own equipment like a virally encoded 
DNA-dependent RNA polymerase and a multitude of RNA-processing enzymes 
(Harrison et al, 2004; Thorne et al, 2005). During replication process, 
components are sheltered by so called “mini-nuclei”, membranes derived from 
the rough endoplasmic reticulum (Schramm & Locker, 2005; Tolonen et al, 
2001). Viral replication is accompanied by transcription and translation of 
intermediate and late genes, the resulting proteins contribute to the correct 
assembly of viral progeny (Schramm & Locker, 2005).  
Starting as IMV, the most abundantly produced form, vaccinia virus leaves the 
host cell only via cell lysis. The IEV is additionally wrapped in an intracellular 
membrane derived from endosome or trans-Golgi network, while the CEV 
occurs after fusion of an IEV with the cell membrane. Thus, as soon as 6 hours 
post infection (hpi), a direct cell-to-cell spread becomes feasible (Thorne et al, 
2005). EEV is the released version of a CEV and able to spread systemically 
(Thorne et al, 2005). While IMV and EEV differ antigenically, CEV moves 
without entering the extracellular space, thus, VACV escapes host cell immune 
detection most efficiently (Appleyard et al, 1971; Rodriguez et al, 1987; Turner 







Figure 5. Schematic structure of the intracellular mature virion (IMV) of VACV, modified 
from Mayer (Mayer, 2014) 
An IMV is built up of a viral core, which contains the double-stranded DNA genome associated 
with viral enzymes and regulatory proteins, two lateral bodies with unknown function, and a 
phospholipid bilayer (outer and inner membrane) with several viral surface proteins integrated. 
The use of this modified figure is granted by N. Mayer.  
  
Until now, the real origin of vaccinia virus remains unclear: In the 18th century 
Edward Jenner, who was looking for a vaccine against smallpox, isolated a 
virus strain from milkmaids called “vaccinia” (Jenner, 1800). Since 1958 
vaccinia virus strains had been applied in a worldwide vaccination campaign 
leading to a complete eradiation of smallpox in 1978 (Fenner, 1993). In the 
1930th, Downie clarified that the applied vaccine strains differ significantly from 
Jenner´s cowpox isolate (Downie, 1939). Despite this knowledge gap 
concerning its origin, vaccinia virus is one of the best studied and most applied 
vaccines we know (Thorne et al, 2005). Through years of vaccination program 
many different vaccinia virus constructs have been developed, not least to 
reduce adverse effects, which occurred commonly after immunization with first 
generation vaccines (Lane et al, 1969; Walsh & Dolin, 2011). Besides its role in 
smallpox eradication, engineered vaccinia virus has been applied as a vaccine 
vector against infectious diseases and cancers (Jager et al, 2006; Kanesa-
thasan et al, 2000; Rochlitz et al, 2003), established itself as a “research tool” to 




investigate eukaryotic cells and, finally, revealed oncolytic activity (Kirn & 
Thorne, 2009; Thorne et al, 2005). 
Wild type vaccinia virus has the ability to adapt host cells for virus replication 
and spreading by expression of virally encoded vaccinia growth factor (VGF) 
and thymidine kinase (TK) (Kirn & Thorne, 2009). VGF, as an EGF homologue, 
activates EGFR-RAS signaling pathways, while viral TK increases the number 
of nucleotides, which are necessary for virus replication (Buller et al, 1985; 
Buller et al, 1988; Kirn & Thorne, 2009). Furthermore, virally encoded 
immunosuppressive proteins, like B18R, block effectively emerging antiviral 
response (Kirn & Thorne, 2009; Symons et al, 1995). In order to reduce 
pathogenicity of wild type vaccinia virus, numerous attenuated versions miss 
functional VGF, TK or immunosuppressive protein synthesis. According to these 
restrictions, mutants are targeted to malignant cells, whereas normal tissue is 
affected to a limited extent only.  
In this thesis we applied GLV-1h254, a relative of well examined GLV-1h68, 
both derived from the LIVP strain (Lister strain from the Institute for Research 
on Viral Preparations, Moscow, Russia). LIVP was generated from Lister strain, 
an attenuated vaccine used extensively during smallpox eradication (Sugimoto 
& Yamanouchi, 1994). GLV-1h68, established in 2007 by Zhang et al., encodes 
Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP), ß-
galactosidase and ß-glucuronidase by genetic engineering of the nonessential 
gene loci F14.5L, J2R (viral TK) and A56R (haemagglutinin/HA) (Zhang et al, 
2007). By deletion of viral TK and inactivation of A56R, GLV-1h68 is 
significantly attenuated but maintains genetic stability and competence of 
replication (Zhang et al, 2007). GLV-1h254 was designed by using GLV-1h71, a 
RUC-GFP- version of GLV-1h68, as starting strain (Chen et al, 2011; Wang et 
al, 2013). GLV-1h254 itself encodes red light-emitting TurboFP635, a 
polypeptide, which gene expression cassette was inserted in the HA locus of 











Figure 6. VACV-derived vector GLV-1h254 (encoding TurboFP635), taken from Wang et 
al. (Wang et al, 2013).  
The unrestricted use of this figure is granted by the publisher. 
 Evaluated human cancer cell lines 
In pretests, ACHN, HCT15 and KM12, three solid human tumor cell lines, 
received from the U.S. National Cancer Institute´s NCI 60 panel (Shoemaker, 
2006), were screened for primary high-grade resistance to both VACV and 
MeV. These pretests were either conducted by our group ((Noll et al, 2013), 
unpublished data by C. Raff respectively) or by other authors (Ascierto et al, 
2011). Furthermore, CCS and SRH, two soft-tissue sarcoma cell lines of human 
origin, which were established and characterized at the University Children´s 
Hospital Tübingen, were defined resistant towards MeV treatment by Berchtold 
et al. (Berchtold et al, 2013). Several preclinical and clinical trials dealt with 
oncolytic vaccinia virus strains and their potential application to human 
sarcomas. For example, vaccinia strain GLV-5b451, encoding an Anti-VEGF 
single-chain antibody, has been brought into place against four canine cancer 
cell lines including soft-tissue sarcoma (Adelfinger et al, 2015). GLV-1h68 has 
shown promising results when applied to four human sarcoma cell lines in vitro 
and in vivo (He et al, 2012). Moreover, GLV-1h68 used in combination with 
chemotherapy, surgery and radiation treatment increased cytotoxic effects to at 
least some soft-tissue sarcoma cell lines in an animal model (Wilkinson et al, 
2016). Nevertheless, to our knowledge, sarcoma cell lines SRH and CCS have 
not been inoculated with oncolytic vaccinia virus strains so far.  
In order to evaluate whether there is a synergistic potential of a sequential 
inoculation applying vaccinia virus GLV-1h254 and Edmonston B vaccine strain-




derived reporter gene vector MeV-GFP, we here established a novel treatment 
regime.  
As outlined before for VV and VSV (section 1.3.4.1), we considered the 
combined application of DNA-based vaccinia and RNA-based measles virus to 
be appropriate due to a variety of reasons. VACV and MeV convince with 
outstanding safety profiles, since both virus constructs have been used in 
worldwide vaccination programs (Fenner, 1993; Griffin et al, 2008). Their 
oncolytic potency has been demonstrated in numberless preclinical (Blechacz 
et al, 2006; Grote et al, 2001; Guo et al, 2005; Kim et al, 2006; Kirn et al, 2007; 
McCart et al, 2001; McDonald et al, 2006; Myers et al, 2008; Peng et al, 2001; 
Phuong et al, 2003; Thorne et al, 2007; Zhang et al, 2007) and clinical (Downs-
Canner et al, 2016; Galanis et al, 2015; Galanis et al, 2010; Gomella et al, 
2001; Heinzerling et al, 2005; Heo et al, 2013; Mastrangelo et al, 1999; Mell et 
al, 2017; Park et al, 2008; Zeh et al, 2015) trials.  
What is more, VACV and MeV were supposed to complement each other in 
terms of genetic and immunogenic diversity (Griffin et al, 2008; Miller et al, 
2008; Putz et al, 2006; Turner & Squires, 1971), packaging capacities (Smith & 
Moss, 1983; Zuniga et al, 2007), replication time (Kirn & Thorne, 2009; Lamb & 
Kolakofsky, 2001) and diverse susceptibility to host cellular IFN response 
(Colamonici et al, 1995; Fontana et al, 2008; Kirn et al, 2007; Ohno et al, 2004; 
Takaki et al, 2011). 
In fact, Noll et al. demonstrated that in ACHN and HCT15 cells, which were 
found to be high-grade resistant to both MeV-SCD and MeV-GFP treatment, a 
strong IFN release was initiated upon MeV-SCD infection (Noll et al, 2013). 
Among other findings, like reduced primary infection rates, altered viral growth 
curves and correspondingly reduced expression of virus-encoded proteins in 
these cell lines, this finding indicates that the incomplete blockage of the innate 
cellular immune defense serves as one mechanism of action of reduced 
sensitivity of high-grade resistant tumor cell lines to measles vaccine virus 





Correspondingly, Berchtold et al. screened eight sarcoma cell lines to 
investigate whether these cells reveal susceptibility to oncolytic MeV-SCD and 
MeV-GFP treatment (Berchtold et al, 2013). Indeed, three cell lines, CCS, SRH 
and SCOS, were found to be resistant to MeV infection (Berchtold et al, 2013). 
CCS, SRH and SCOS cells showed lower primary infection rates and achieved 
only poor virus titers in viral growth assays, when compared to susceptible 
sarcoma cell lines. Although reduced CD46 expression and the absence of 
SLAM or nectin-4 offered a first explanation for these findings, further data 
supported the idea that the inhibition of replication accompanied by IFN-
dependent host cellular response are of quite more importance (Berchtold et al, 
2013). Of note, the researchers were unable to identify a clear correlation 
between the induction of other intracellular receptors, like Toll-like receptor 3 
and melanoma differentiation-associated gene 5, and the induction and 
secretion of IFN-ß upon MeV-SCD infection and resistance patterns (Berchtold 
et al, 2013).  
However, to buy into Berchtold et al.: “These data suggest that resistance to 
virotherapy is at least in part due to elevated levels of cytoplasmic pathogen 
receptors and ISGs” (Berchtold et al, 2013). 
As described before (section 1.3.4.1), VVDD revealed an IFN-dependent 
antiviral response mechanism, due to expression of B18R, which most 
effectively supported coinfection by VSVΔ51 (Le Boeuf et al, 2010). Tysome et 
al. assumed that synergistic interactions of oncolytic adenovirus and VV are at 
least in part due to altered IFN signaling (Tysome et al, 2012). Although 
susceptibility of human cancer cell lines to GLV-1h68 seemed to be 
multifactorial conditioned, Ascierto et al. highlighted that downregulated IFN 
signaling of susceptible cells should be taken into account (Ascierto et al, 2011). 
Consequently, we expected VACV GLV-1h254, as a GLV-1h68 relative, and 
MeV-GFP to complement each other in any possible way.  
  




1.5 Aim of this thesis 
Although oncolytic virotherapy is an exciting new approach in cancer treatment, 
a wide array of human tumors exhibits primary resistance towards it.  
In prior work, ACHN, HCT15 and KM12, three solid human tumor cell lines 
originating from renal and colon cancer, respectively, were identified highly 
resistant to both VACV and MeV treatment. Additionally, CCS and SRH, two 
soft-tissue sarcoma cell lines of human origin, were defined resistant to MeV-
derived virotherapeutics.  
Here, we investigated whether a combinatorial treatment regime applying two 
virotherapeutic vectors of completely different origins in the sense of a double-
infection, i.e., VACV-derived vector GLV-1h254 (encoding TurboFP635) and 
MeV-GFP (encoding GFP), was able to overcome remaining limitations.  
First, appropriate virus concentrations at which cell masses of ACHN, HCT15, 
KM12, SRH and CCS cells were reduced less than 25 % were determined in 
single infection approaches.  
Thereafter, different schemes of sequential infections using altering orders of 
virus treatment, time points of secondary infection and dosages were con-
ducted.  
Then, we examined whether synergistic or additive effects explained improved 
cell death registered upon double-infections and investigated virus-specific 
marker protein expression by electrophoresis and western blot.  
In addition, we also analyzed the impact of plating densities on confluence, 
virus spreading and oncolysis and described a phenomenon called “viral 
competition”, which is novel to double-infections combining virotherapeutics of 
vaccinia virus and measles vaccine virus origin.  




2 Material and Methods  
 
2.1 Material 
Unless otherwise identified, all mentioned materials and chemicals have been 
used in the highest possible purity. They were either declared as sterile goods 
or autoclaved at 121°C and 2 bar for 20 minutes. Deionized and additionally 
filtered water (H2Odd) has been used in all experiments, otherwise it is declared 
differently. 
 Consumables and Chemicals 
Cell scraper Corning Inc. 
Cell strainer 40 µm BD Falcon 
Combitips 2.5/5/12 ml Eppendorf 
Conical tube 1.5 ml Biozym 
Conical tube 2.5 ml Biozym 
Conical tube/Falcon 15 ml Greiner Bio-one, Corning Inc. 
Conical tube/Falcon 50 ml Corning Inc. 
Cryo tubes 1 ml Corning Inc. 
Reaction tubes 500/1500/2000 µl, safe lock Eppendorf 
Flat bottom 96 well plate  Greiner Bio-one 
Tissue culture dishes 15 cm Costar 
Tissue culture E-plate 96 well Roche Applied Science 
Tissue culture flask 25/75/150 cm² Greiner Bio-one, TPP 
Tissue culture plate 24 well TPP 
Tissue culture plate 6 well Falcon, Corning Inc. 
Tissue culture plate 96 well Falcon, TPP 
Pasteur pipets WU Mainz 
Pipets 5/10/25/50 ml Costar, Corning Inc.  
Pipet tips 10/100/200/1000 µl Biozym, PEQLAB 
Pipet tips for multichannel pipet 1200 µl Eppendorf 




Descosept  Dr. Schuhmacher GmbH 
Isopropanol (70 %) SAV Lp GmbH 
Sekusept ECOLAB 
Sterillium BODE Chemie Hamburg 
Fuji Photo Film LTD 
HyperfilmTM ECL Amersham Biosciences 
Parafilm Bemis Company, Inc. 
PVDF membrane Amersham Biosciences 
Precision wipes Kimberley Clark 
Latex and nitrile gloves Ansell, Hartmann  
Mycoplasma detection kit Roche 
Sponges Amersham Biosciences 
Whatman papers Amersham Biosciences  
 
Acetic Acid Merck 
Acrylamide Rotiphorese Gel 30 Carl Roth 
APS 10 % Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
CMC Sigma-Aldrich 
Crystal violet dye  Carl Roth  
DMSO AppliChem   
ECL solution (western blotting detection  Amersham Biosciences 
Reagents and analysis system, 0.125 ml/cm2) 
Ethanol  Carl Roth 
Formaldehyde Carl Roth 
Full Range Rainbow Protein Marker Amersham Biosciences 
Glycerol 86 % Carl Roth 
Glycine Carl Roth 
H2Odd MilliQ Synthesis System 
HCI Carl Roth 
IGEPAL PA-630 (10 %) Sigma-Aldrich 
KCl Carl Roth  




KH2PO4  Carl Roth 
Milk powder Carl Roth 
NaCl Merck 
Na2HPO4 Carl Roth  
NaN3  Sigma-Aldrich 
PFA 4.0 % Otto Fischar GmbH 
SDS Carl Roth 
SRB Sigma-Aldrich 
Sucrose Carl Roth 
TCA Carl Roth 
TEMED Carl Roth  
TRIS  Carl Roth 
Triton-X-100  Carl Roth 
Trypan blue solution 0.4 % Sigma-Aldrich 
Tween-20  Sigma-Aldrich  
2-mercaptoethanol Carl Roth 
 
 Antibodies (Western Blot) 
Target Name, species Dilution, Buffer Source 




Human vinculin V9131, mouse 1:5000 in TBS-Tween, 





1:200 in TBS-Tween Invitrogen 
ß-actin Anti-ß-actin, mouse 1:5000 in TBS-Tween, 





1:500 in TBS-Tween, 
NaN3 (0.05 %) 
abcam 
MeV N-Protein Ab23974, rabbit 1:1000 in TBS-Tween, 
NaN3 (0.05 %) 
abcam 
Mouse IgG HRP-coupled, goat 1:4000 in TBS-Tween BioRad 
Rabbit IgG HRP-coupled, goat 1:4000 in TBS-Tween BioRad 





 Media, Sera and Buffer 
DMEM   BIOCHROME, Sigma-Aldrich 
(with stable L-glutamine, 4.5 g/l glucose) 
EDTA-Trypsin (0.05 % Trypsin) Lonza, Sigma-Aldrich 
FBS BIOCHROME, Gibco 
OPTI-MEM® Gibco 





Acidified isopropanol (e.g. 30 ml)  HCl 3 ml 
(10 % HCl in Isopropanol) Isopropanol (70 %) 27 ml 
 
CMC medium CMC 7.5 g 
 DMEM 495 ml 
 FBS 25 ml 
 Pen/Strep  5 ml 
   
Crystal violet stain Crystal violet (408.6 g/mol) 1.3 g 
(Crystal violet 0.13 %, Ethanol 5 %, Formaldehyde 37 % 300 ml 
Formaldehyde 11.1 %) Ethanol 100 % 50 ml 
 H2Odd filled up to 1 l 
 
2 % FBS-supplemented DMEM DMEM 500 ml 
Inactivated at 56 °C for 30 minutes: FBS 10 ml 
 Storage at  4 °C 
  




10 % FBS-supplemented DMEM DMEM 500 ml 
Inactivated at 56 °C for 30 minutes: FBS 50 ml 
 Storage at  4 °C 
 
22 % FBS-supplemented DMEM DMEM 50 ml 
Inactivated at 56 °C for 30 minutes: FBS 11 ml 
Prepared prior to use Storage at  4 °C 
 
26 % FBS-supplemented DMEM DMEM 50 ml 
Inactivated at 56 °C for 30 minutes: FBS 13 ml 
Prepared prior to use Storage at  4 °C 
 
Freezing medium (e.g. 25 ml) DMEM 17.5 ml 
(70 % DMEM, 20 % FBS and 10 % DMSO) FBS 5 ml 
 DMSO 2.5 ml 
 
Loading buffer (6x) TRIS 1 M pH 6.8 37.5 ml 
 Glycerol 86 % 30 ml 
 SDS 12.3 g 
 Bromophenol blue 60 mg 
 H2Odd filled up to 100 ml 
Prior to use: 2-mercaptoethanol 60 µl/ml 
 
Lysis buffer stock solution (50 ml) TRIS 1 M pH 7.6 50 mM (5 ml) 
 NaCl 5 M 150 mM (3 ml) 
 IGEPAL PA-630  
 (10 %)  1% (10 ml)   
 H2Odd 32 ml 
 Storage at  4 °C 
 
MTT stock solution (30 ml) MTT      75 mg (2.5 mg/ml) 
 colorless DMEM 30 ml 




 filtered (pore size 0.45 µm) and  
 dissolved at 37 °C water bath   
 
PAGE buffer (1x) TRIS 125 mM (15.1 g/l) 
 Glycine 72 g/l 
 SDS 5 g/l 
 H2Odd filled up to 1 l 
 pH 8.3 
 
PBS (not used in cell culture) NaCl 137 mM (8 g) 
 KCl 2.7 mM (0.2 g) 
 Na2HPO4 10 mM (1.44 g) 
 KH2PO4 1.8 mM (0.24 g) 
 H2Odd filled up to 1 l 
 
8 % resolving gel (15 ml) H2Odd 6.9 ml 
 30 % acrylamide mix 4.0 ml 
 1.5 M TRIS pH 8.8 3.8 ml 
  SDS 10 % 0.15 ml 
 APS 10 % 0.15 ml 
 TEMED 0.009 ml 
 
15 % resolving gel (15 ml) H2Odd 3.4 ml 
 30 % acrylamide mix 7.5 ml 
 1.5 M TRIS pH 8.8 3.8 ml 
 SDS 10 % 0.15 ml 
 APS 10 % 0.15 ml 
 TEMED 0.006 ml 
  
SRB dye (0.4 % in 1 % acetic acid) SRB 4 g 
 Acetic acid 10 ml 
 H2Odd filled up to 1 l 




5 % stacking gel (10 ml) H2Odd 6.8 ml 
 30 % acrylamide mix 1.7 ml 
 1.0 M TRIS pH 6.8 1.25 ml 
 SDS 10 % 0.1 ml 
 APS 10 % 0.1 ml 
 TEMED 0.01 ml 
 
Stripping buffer TRIS 1.0 M (3 ml) 
 SDS 10 % 10 ml 
 2-Mercaptoethanol 
  100 mM (340 µl) 
 H2Odd 47.5 ml 
  
10 x TBS NaCl 1.5 M (438.3 g) 
 TRIS 0.5 M (302.85 g) 
 pH     7.4, adjusted with HCl 
 H2Odd filled up to 5 l 
 
TBS-Tween (0.02 %) Tween-20  5 ml of 20 % 
 10 x TBS 500 ml 
 H2Odd filled up to 5 l 
 
TCA solution (10 %) TCA 100 g 
 H2Odd filled up to 1 l 
 
Transfer buffer (10x)  Glycine 390 mM (146.25 g) 
 TRIS 435 mM (264 g) 
 H2Odd filled up to 5 l 
 
Transfer buffer (1x) Transfer buffer (10x) 280 ml 
 MeOH 560 ml 
 H2Odd filled up to 2.8 l 





TRIS base buffer (10 mM, pH 9, 5 % sucrose) TRIS 10 mM (1.21 mg/100 ml) 
sterile-filtered  H2Odd filled up to 100 ml 
 Sucrose 5 g 
 pH 9, adjusted with HCl 
 
TRIS solution (10 mM, pH 10.5) TRIS 10 mM (1.21 g/l) 
 H2Odd filled up to 1 l 
 pH 10.5, adjusted with HCl 
 
TRIS solution (1.0 M, pH 6.8) TRIS  1 M (121 g/l) 
 H2Odd filled up to 1 l 
 pH 6.8, adjusted with HCl 
 
TRIS solution (1.0 M, pH 7.6) TRIS  1 M (121 g/l) 
 H2Odd filled up to 1 l 
 pH 7.6, adjusted with HCl 
 
TRIS solution (1.5 M, pH 8.8) TRIS 1.5 M (181.71 g/l) 
 H2Odd filled up to 1 l 
 pH 8.8, adjusted with HCl 
   










 Cell lines 






human kidney cancer 











human colorectal adenocarcinoma 














human colorectal adenocarcinoma 










sclerosing spindle cell rhabdomyosarcoma 
Species: human 
Source: established and characterized at the 










CCS   
 
clear cell sarcoma 
Species: human 
Source: established and characterized at the 








African green monkey kidney epithelial cells 
Species: simian 
Source: German Collection of 









African green monkey kidney fibroblasts 
Species: simian  
Source: ATCC® CCL-70TM 
 
Bright-field picture, modified from Mayer (Mayer, 





All cell lines were cultivated as permanent cell cultures, and grew as adherent 
monolayers in Dulbecco´s modified Eagles medium (DMEM) supplemented with 
10 % fetal bovine serum (FBS) in culture flasks. 
 
 





MeV-GFP Wolfgang Neubert 
VACV GLV-1h254 Genelux Corp. 
 Laboratory Equipment 
All-in-one BZ-9000 fluorescence microscope KEYENCE 
Autoclave 3850 EL Systec 
Autoclave VARIOKLAV HP Medizintechnik GmbH 
Banded ear protectors Peltor 
Blotting system BioRad 
Centrifuge Eppendorf, Heraeus 
Counter LVP 
Cylinder & beaker 500/1000/2000 ml  Hirschmann, VITLAB, VWR 
Cryo Freezing Container (Mr. Frost) Nalgene  
Laboratory bottle, Duran Schott 
Electronic pipet Eppendorf 
Electrophoresis chamber Amersham Biosciences 
Fluorescence microscope Olympus 
Forceps Servoprax 
Freezing cabinet (-150 °C)  Sanyo 
Gel caster Amersham Biosciences 
Haemocytometer Hecht Assistant 
Heating cabinet Binder 
High-definition camera, F-view Soft Imaging System GmbH 
lncubator Heraeus, Memmert 
Laminar Flow Work Bench Heraeus 
Light microscope Olympus 
Magnetic stirrer IKA Labortechnik 
Manual repeating pipet (Multistep) Brand 
Microchronometer Oregon Scientific 
Microtiter plate reader (Tecan GENios) Tecan  




Multichannel pipette Eppendorf 
pH controller Hanna instruments 
Photo cassette Dr. GOOS Suprema GmbH  
Pipet Boy Integra  
Pipets Eppendorf  
Precision scale Sartorius 
Refrigerator (-20 °C) Liebherr  
Refrigerator (-80 °C)  Heraeus, Forma Scientific, 
Skadi 
Shaker Heidolph 
Thermostatic circulator 2219 Multitemp II LKB Bromma 
Ultrasound Sonifier 450 Branson 
Vortexer Vibrofix Electronics Janke+Kunkel IKA 
  Labortechnik 
Water bath 342 (37 °C) Köttermann 
xCELLigence SP system  Roche Applied Science 











All experimental work was done in laboratories with Biosafety Level 2 approval 
(BSL2, Directive 2000/54/EC). Infectious virus particles or precarious organics 
were treated under laminar flow hoods. All materials and laboratory equipment 
were both disinfected and inactivated by UV ray (at least 15 minutes) as well as 
autoclaved whenever possible. 
 Cell culture 
All cell lines were cultured in 75 cm2 tissue culture flasks with vented caps in 
DMEM supplemented with 10 % FBS without any antibiotics added. Flasks 
were incubated at 37 °C in a humid atmosphere containing 5 % CO2. All work 
was done in a laminar flow work bench under sterile conditions. Cell lines were 
tested for mycoplasma contamination at regular intervals with a mycoplasma 
detection kit. During cultivation, cell lines were examined regularly under a light 
microscope with a 4 - 10 x objective to ensure subconfluent growth of the 
monolayer and to detect any lack of nutrients or contamination.  
Before use, FBS and EDTA-Trypsin were stored at -20 °C and FBS was heat-
inactivated at 56 °C for 30 minutes. Open bottles of FBS, EDTA-Trypsin, media 
and PBS were stored in the fridge at 4 °C. Prior to use, media, PBS and EDTA-
Trypsin were warmed in the water bath at 37 °C unless otherwise specified.  
 General cell culture 
For harvesting of cells, DMEM was removed with a pipet and cells were washed 
with PBS. Thereafter, cells were incubated with 1 ml EDTA-Trypsin at 37 °C 
and flasks were agitated gently until the cell layer came off. Subsequently, 
EDTA-Trypsin was inactivated with 9 ml 10 % FBS-supplemented DMEM and 
cells were resuspended by using a pipet. If necessary, the cell suspension was 
additionally filtered through a 40 µm cell strainer. To split cells, one half of the 
generated single cell suspension was transferred to a new tissue culture flask 




and filled up with fresh medium supplemented with 10 % FBS. Split ratios of 
different cell lines diversified and were empirically determined. Culture flasks 
were stored in the incubator at 37 °C.  
2.2.3.1 Counting cells with a haemocytometer 
In order to plate cells, it was necessary to define the number of viable cells in 
the created cell suspension. Accordingly, 10 µl of the cell suspension were 
added to 90 µl of Trypan blue solution, a diazo dye, to generate a 1:10 dilution. 
Trypan blue is used to differentiate between dead and viable cells. As living 
cells appear highlighted, dead cells appear dark blue, when analyzed under a 
light microscope. Unless otherwise specified, Trypan blue was used for all 
counting. 
Cells were counted by using an improved Neubauer counting chamber. The 
Newton ring, a light reflection that appears when the covering glass is rubbed 
against the chamber, indicates that the covering glass is fixed accurately, which 
is essential to guarantee a gap of no more than 0.1 mm. Accordingly, one 
square contains a define volume of 0.1 µl. After the chamber was assembled 
correctly, 10 to 12 µl of the prepared 1:10 dilution were transferred to one 
corner of the chamber. Depending on capillary forces, the volume now 
distributed equally over the squares. Every living cell in a large square, 
consisting of 16 smaller squares, was now counted properly under a light 
microscope with a 10 x objective. The factor of dilution was taken under 
consideration by multiplication by 10. Accordingly, the concentration of cells 





𝑡𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
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2.2.3.2 Plating of cells 
After calculating the concentration of viable cells via haemocytometric 
technique, the desired concentration for plating was diluted using 10 % FBS-
supplemented DMEM. Most cell lines were plated in 0.5 ml cell suspension/well 
at a density of 5 x 104 cells per well in 24-well plates. Cells were seeded with a 
manual repeating pipet and incubated at 37 °C for one to two nights depending 
on the cell line processed. 
2.2.3.3 Confluence trials 
Tumor cell confluence, which is required for optimal virus spreading, was 
analyzed for each cell line in separate pretests. Thus, cells were plated at 
different densities in 24-well plates and examined under a light microscope with 
a 4 - 10 x objective up to 6 days. The extent of the reached confluence, 
expressed as percentage, as well as the consumption of media and the 
detachment of cells were documented daily. 
2.2.3.4 xCELLigence system for monitoring of cell viability and virus spreading  
The xCELLigence system allows to monitor real-time cell viability and cell 
proliferation by the measurement of electrical impedance. Interdigitated micro-
electrodes, which are integrated in special 96-well E-plates, register changes of 
electrical impedance. The readout, displayed as cell index, provides information 
about cell viability and correlates well with the actual cell number. Thereby, the 
xCELLigence system helps to review the chosen cell counts and selected time 
points to run cell viability assays like SRB and MTT assay (Ke et al, 2011). In 
addition, it may clarify the impact of cell confluence on the efficiency of virus 
spreading. 
In order to determine suitable cell numbers for the following xCELLigence trial, 
cells were plated in sextuplicates in 200 µl 10 % FBS-supplemented DMEM at 
various densities in a 96-well plate. The next day, cells were either infected with 
VACV GLV-1h254 or mock-treated in 20 µl 2 % FBS-supplemented DMEM. 




Cells were incubated until 96 hpi. Virus infection and spreading, as well as the 
development of confluence were evaluated under a fluorescence microscope. 
Virological methods are described in detail in section 2.2.4.1.1.  
For xCELLigence trial, cells were split one day before plating to avoid growth 
inhibition. The following day, 50 µl of 10 % FBS-supplemented DMEM were 
added to each well of a 96-well E-plate and a background measurement was 
performed. Thereafter, cells were plated at the selected densities in 100 µl 
2.5 % FBS-supplemented DMEM. Thus, a final concentration of 5 % FBS was 
obtained. The E-plate was incubated at 37 °C overnight. At 22.5 hrs after 
plating, cells got either infected in triplicates with VACV GLV-1h254 in 10 µl 
DMEM or were mock-treated. Triton 0.1 % X-100, which was used as a positive 
control for cell death, was applied to three wells of each plating density. At 
1.5 hpi, 50 µl of 26 % FBS-supplemented DMEM were added to each well to 
receive a final concentration of 10 % FBS in a total volume of 210 µl. Electrical 
impedance was measured every 30 minutes, starting after seeding of the cells 
until the experiment was ended (after an observation period of approximately 
130 hrs). Electrical impedance was measured using the xCELLigence SP 
system. RTCA Software 1.2 was applied to calculate cell index values. All 
values were normalized. 
2.2.3.5 Cryoconservation and thawing of cells 
Cells in tissue culture flasks were first examined under a light microscope with a 
4 - 10 x objective to evaluate the density of the cell layer. Confluent but not 
overgrown cells were favorite to generate a concentrated cell suspension. 
Freezing medium, containing 70 % DMEM, 20 % FBS and 10 % DMSO, was 
prepared next. Cells were harvested as outlined above and settled by 
centrifuging at 1200 rpm for 3 minutes at 22 °C. Cell supernatant was 
discarded, the cell pellet was resolved in the prepared freezing medium and the 
cells were resuspended carefully with a 25 ml pipet. The volume was distributed 
to cryo tubes, 1 ml each. The last cryo tube served as a sterility check and was 
labelled. Cryo tubes were frozen with an isopropanol bath at -80 °C for one day 
and transferred afterwards to a freezing cabinet at -145 °C or into liquid nitrogen 




for long time storage. The labelled cryo tube was thawed the next day and 
checked for growth behavior and contamination.  
For thawing, frozen cryo tubes were shortly dipped into the water bath (37 °C). 
The defrosted cell suspension was transferred with 9 ml of FBS-supplemented 
DMEM into a conical tube and resuspended carefully. Thus, DMEM inactivates 
the cytotoxic DMSO. Cells were now centrifuged at 1200 rpm for 2 minutes, 
supernatant was removed and the remaining cell pellet was resuspended in 
10 ml fresh FBS-supplemented DMEM. The cell suspension was then 
transferred into a fresh culture flask.  
 Virological methods 
2.2.4.1 Infection of cells 
2.2.4.1.1 Single virus infection with VACV GLV-1h254 
Plates were labelled with the assay number, plate number and date. Cells were 
seeded in 0.5 ml cell suspension/well at the determined plating density in 24-
well plates. Plates were incubated at 37 °C for one to two nights depending on 
the cell line processed. On the infection day, the plates were examined under a 
light microscope to check for sufficient cell adherence and a subconfluent 
monolayer. The current cell count of each cell line was determined via 
haemocytometer technique, as described above, and calculated as an average 





𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑎𝑟𝑔𝑒 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑥 104 𝑥 𝑓𝑎𝑐𝑡𝑜𝑟 𝑜𝑓 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛)/4 
 
The following calculation of multiplicity of infection (MOI) based on the received 
cell count. To exemplify, MOI 1 stands for one infectious virus particle per cell at 
the time point of infection. The following formula calculates the required volume 
(amount of virus in µl) of the virus stock which is needed to create a virus 
dilution that fit the counted cell number/well at the determined MOI:  
 













𝑣𝑖𝑟𝑢𝑠 𝑡𝑖𝑡𝑒𝑟 (𝑝𝑓𝑢 𝑚𝑙⁄ )
∗ 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 (µ𝑙) 
 
Virus aliquots were thawed carefully for a few seconds in the water bath 
(37 °C). Subsequently, aliquots were vortexed and sonicated three times 
30 seconds each and intercalated on ice again. Now, the calculated amount of 
virus was diluted in 2 % FBS-supplemented DMEM. Since cells were infected at 
various MOIs, a serial dilution, starting with the calculated virus dilution, was 
prepared. Therefore, virions were diluted in DMEM supplemented with 2 % 
FBS. 
DMEM was removed from the cells and each well was washed carefully with 
0.5 ml PBS. Next, 100 or 150 µl 2 % FBS-supplemented DMEM were added to 
each well to prevent cells from drying out. Now, cells were either infected with 
GLV-1h254 at ascending viral concentrations in 100 or 150 µl 2 % FBS-
supplemented DMEM or mock-treated (only medium was added). Plates were 
incubated at 37 °C and agitated gently every 20 minutes to allow the virus 
suspension to disperse equally. At 1.5 hpi, the inoculum was removed and 
every well was filled with 500 µl 10 % FBS-supplemented DMEM. Respectively, 
in experiments where it was important to keep the inoculum on the cells, 200 µl 
22 % FBS-supplemented DMEM were added without removing the inoculum to 
receive a final concentration of 10 % FBS-supplemented DMEM. Plates were 
stored in the incubator for maximum 96 hpi. 
2.2.4.1.2 Single virus infection with MeV-GFP  
Plates were labelled as described above. Cells were seeded confluence-
optimized in 24-well plates and incubated overnight, respectively for two nights. 
Cell adherence and confluence were evaluated under a light microscope prior to 
infection. The current cell count was calculated as detailed in section 2.2.3.1 for 
each cell line separately.  




The measles vaccine virus (MeV-GFP) was thawed on ice and vortexed briefly. 
Every aliquot was used only once after thawing. To infect cells at various MOIs, 
a serial dilution with room-tempered OPTI-MEM® was prepared. Next, the 
medium was removed carefully from the wells, cells were washed with PBS and 
150 µl of OPTI-MEM® were pipetted to the cells. The infection medium or only 
OPTI-MEM® were added in 100 µl suspension per well. Plates were incubated 
at 37 °C and agitated gently every 20 minutes until 1.5 hpi. After 1.5 hrs 
absorption period, the inoculum was removed and replaced by 500 µl of 
10 % FBS-supplemented DMEM. Plates were placed in the cell culture 
incubator for 96 hpi.  
2.2.4.1.3 Combined infection with VACV GLV-1h254 and MeV-GFP  
For each experiment we needed at least four 24-well plates and an additional 
plate for cell counting, labelled as mentioned above. For Keyence microscopy, 
cells were plated in an open µ-Slide with 8 wells, respectively. After plating, 
cells were incubated at least overnight. The next day, the plates were examined 
for cell adherence and extent of confluence. On the infection day, the current 
cell count was calculated as explained above. Each virus and its serial dilution 
was prepared separately. VACV was treated as described in section 2.2.4.1.1. 
A serial dilution of measles vaccine virus was performed by the use of 2 % FBS-
supplemented DMEM instead of OPTI-MEM®. 
Now, medium was removed from the plates, cells were washed with PBS and 
150 µl of 2 % FBS-supplemented DMEM were added to each well. Cells were 
inoculated with the first virus at various MOIs in a volume of 100 µl/well or 
mock-treated. The plates were stored in the incubator and swayed in 20-
minutes periods. The second virus was added in a volume of 50 µl at diverse 
time points, while mock-treated and single-infected cells were inoculated with 
50 µl 2 % FBS-supplemented DMEM.  
At 1.5 hpi with the second virus, 200 µl DMEM + 22 % FBS were added. Culture 
plates were stored in the incubator for 96 hpi with the first virus. 




2.2.4.2 Amplification of MeV 
To produce a sufficient amount of measles vaccine viruses, Vero cells were 
plated in 10 % FBS-supplemented DMEM in 15 cm culture dishes, each dish 
containing 1 x 107 cells. Culture dishes were incubated overnight at 37 °C. Vero 
cells were chosen for amplification, as they guarantee an optimal environment 
for the replication of measles vaccine virus (Griffin, 2001).  
On the infection day, medium was removed from subconfluent monolayers, 
cells were washed once with PBS and incubated with 9 ml OPTI-MEM®. 
Subsequently, Vero cells were infected with MeV-GFP at MOI 0.03 in 1 ml 
OPTI-MEM® and incubated for 3 hrs at 37 °C. During this incubation period, 
dishes were gently agitated for an equal disperse of the virus suspension. The 
inoculum was discarded at 3 hpi, and culture dishes were filled with 20 ml 
10 % FBS-supplemented DMEM. Dishes were stored in the incubator for 
another 48 hrs. 
Best conditions for harvest were indicated on the one hand by the extent of 
syncytia building, and on the other hand by the attachment of virus particles to 
the cell surface. Accordingly, virus spreading and syncytia building were 
examined under both a light and a fluorescence microscope daily. On the 
harvesting day, supernatant was removed and 1 ml OPTI-MEM® was added to 
each dish. The cell layer was popped off with a cell scraper and cells were 
assembled in a 50 ml conical tube. The tube was quickly frozen in liquid 
nitrogen at -160 °C and subsequently stored at -80 °C. This freezing process 
broke off the cell membranes and released the virus particles. Next, the frozen 
tube was thawed quickly in a water bath at 37 °C, vortexed and centrifuged at 
4000 x g for 15 minutes at 4 °C. The centrifugation process separated the cell 
remnants, which accumulate in a cell pellet, from the virus particles in the 
supernatant. The virus suspension was aspirated and transferred into a fresh 
tube, vortexed and distributed to cryo tubes at various volumes (100 µl, 200 µl 
and 500 µl). Finally, the virus aliquots were stored at -80 °C. The amplification 
of MeV-GFP was kindly supported by Irina Smirnov. 





2.2.4.3 Production of vaccinia virus aliquots out of a stock solution 
The vaccinia virus stock solution (VACV GLV-1h254) was kindly provided by 
Genelux Corp., San Diego, USA.  
To yield a more diluted virus suspension, the highly-concentrated virus stock 
solution needed to be diluted and distributed to smaller aliquots. TRIS base 
buffer (10 mM, pH 9), containing 5 % sucrose, was used as dilution volume. 
Accordingly, the virus stock solution was thawed quickly at 37 °C in the water 
bath, vortexed and sonicated 3 x 30 seconds. Thereafter, the stock was stored 
on ice again. Next, 45 µl of the stock solution were pipetted into a 1.5 ml conical 
tube, filled up with 855 µl of sucrose-supplemented TRIS base buffer and 
vortexed again. The obtained virus dilution was now allocated to approximately 
29 cryo tubes, 30 µl each, and stored at -80 °C. 
2.2.4.4 Titration of viruses 
To identify the virus titer of an unknown virus solution, it is essential to perform 
titration assays, both for oncolytic vaccinia and measles vaccine virus.  
2.2.4.4.1 Titration of vaccinia virus 
For the titration of virus aliquots, CV-1 cells were plated in 24-well plates at a 
density which resulted in a confluent monolayer (in this case 4 x 104 cells/well) 
after 24 hrs incubation time. The CV-1 cell line was chosen as it provides a 
suitable environment for the replication of vaccinia virus particles (Liu et al, 
2017). The next day, three virus aliquots were thawed quickly at 37 °C in a 
water bath, vortexed and sonicated 3 x 30 seconds before stored on ice again. 
Serial dilutions with factors from 10-2 to 10-7 were prepared in 2 % FBS 
supplemented DMEM. All tubes were stored on ice again. To guarantee a 
reliable value of the mean, the experimental steps described so far were 
repeated in a second approach using the same aliquot. Furthermore, aliquot 
two and three were processed likewise. Additionally, the whole titration assay 
was repeated using another three aliquots some days later.  




DMEM was removed from the wells and CV-1 cells were infected in 200 µl/well 
at various dilutions in duplicates. Inoculated plates were stored in the incubator 
at 37 °C for one hour, interrupted only by gentle agitation every 20 minutes. 
Subsequently, 1 ml of CMC medium was added to each well, and plates were 
stored in the incubator for another 48 hrs. The CMC medium prohibits a further 
virus spreading through the medium. As a consequence, virus dispersion is 
limited to direct cell-to-cell contact, which forms plaque units (Baer & Kehn-Hall, 
2014). At 49 hpi, 250 µl crystal violet stain were brought carefully to each well 
using a manual repeating pipet. Thereafter, plates were stored overnight at 
room-temperature. Crystal violet terminates the virus infection and stains the 
wells (Baer & Kehn-Hall, 2014). The next day, supernatants were removed, 
plates were washed with H2Odd and dried under UV light. For titration, every well 
was examined with the naked eye under a light source for plaque forming units 
(pfu). These pfu appeared as pale spots on the violet stained background. In 
order to obtain a reliable result, plaques were only counted in wells, which 
showed 10 to 100 pale spots. For the determination of the virus titer, expressed 
in plaque forming units per ml (pfu/ml), we used the following calculation:  
 
𝑉𝐴𝐶𝑉 𝑡𝑖𝑡𝑒𝑟 (𝑝𝑓𝑢 𝑚𝑙) =  
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑙𝑎𝑞𝑢𝑒 𝑐𝑜𝑢𝑛𝑡 (𝑝𝑓𝑢) ∗ 5
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 ∗ 0.2 𝑚𝑙 (𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛) ∗ 5
⁄  
 
The volume of infection (200 µl/well) and the average plaque count were 
multiplied by 5 to obtain the pfu in a volume of 1 ml virus suspension per dilution 
factor (titer is expressed in pfu/ml). The titration of VACV GLV-1h254 was kindly 
supported by Dr. Martina Schell and Dr. Julia Beil.  
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Figure 7. Performance of a serial dilution of vaccinia virus stock solution (A), infection of 
CV-1 cells at various dilution factors (B) and crystal violet stained plate (C) 
First, 4 µl of the virus stock solution were pipetted to a 1 ml conical tube prepared with 396 µl 
2 % FBS-supplemented DMEM. The volume was resuspended and vortexed rigorously, then 
100 µl were transferred to the next tube, which was already filled with 900 µl medium. 
Resuspending and vortexing were repeated, before 100 µl virus suspension were transferred to 
the next tube. This way a serial dilution with six dilution factors (10-2 to 10-7) was established 
(A). For titration assay, CV-1 cells, plated in a 24-well plate, were infected in 200 µl virus 
suspension/dilution factor (from 10-4 to 10-7) in duplicates and incubated at 37 °C (B). For 
plaque counting, the inoculated plate was dyed using crystal violet stain. After a 48 hrs-
incubation period with CMC medium, 250 µl crystal violet stain were brought to each well, the 
plate was stored at room-temperature. The next day, supernatant was discarded and plates 
were washed and dried under UV light. After drying, plaque forming units appeared as pale 











2.2.4.4.2 Titration of measles vaccine virus 
To identify the unknown titer of a measles vaccine virus stock, we performed a 
TCID50 (tissue culture infective dose 50, (Rabenau et al, 2015)) endpoint 
dilution assay, using calculations by Spearman and Kärber (Kärber, 1931; 
Spearman, 1908). Due to reasons of convenience, the received TCID50 unit was 
subsequently converted into pfu/ml.  
First, a sufficient amount of Vero cells was harvested from culture flasks. The 
gained cell suspension was incubated at 37 °C in the water bath before further 
processed. Next, eight wells of a 96-well plate were filled with 270 µl OPTI-
MEM® each. One aliquot of the measles vaccine virus stock was thawed 
carefully as described above (section 2.2.4.1.2). Subsequently, 30 µl of the 
virus suspension were pipetted into the first cavity of the prepared 96-well plate 
and resuspended 5 x. Furthermore, 30 µl of this well were aspirated and 
transferred into the next and resuspended 5 x. This step was repeated until a 
serial dilution with eight dilution factors (10-1 to 10-8) was performed. Now, using 
an 8-channel electric pipet and fresh 200 µl pipet tips, the prepared serial 
dilution was transferred in sextuplicates (30 µl/well) into a fresh 96-well plate. 
The experimental steps described so far were repeated in a second approach.  
 
 





Figure 8. Performance of a serial dilution of measles vaccine virus stock solution (A) and 
preparation of a 96-well plate for titration (B) 
Eight wells of a 96-well plate (A) were filled with 270 µl OPTI-MEM®. Next, 30 µl of the thawed 
virus stock solution were pipetted to the first well, resuspended 5 x and transferred to the 
proximate well, until a serial dilution with eight dilution factors (10-1 to 10-8) was completed. Now, 
using an 8-channel electric pipet, the prepared serial dilution was transferred in sextuplicates 
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Vero cells were now transferred in 200 µl 5 % FBS-supplemented DMEM/well at 
a density of 2 x 104 cells/well to the inoculated 96-well plate. Cells and measles 
virus particles were incubated for four days at 37 °C and observed under a 
fluorescent microscope. The TCID50 was now determined by counting every 
fluorescent cavity as “positive”, irrespective of the extent of cytopathic effect.  
To gain a stable value of the stock titer, another virus aliquot was titrated in the 
described manner. The TCID50, or rather the pfu/ml, was expressed as average 
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101+∑ 𝑖𝑛𝑓𝑒𝑐𝑡𝑒𝑑 𝑤𝑒𝑙𝑙𝑠−0.5 𝑥 log 10
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TCID50-formula by Spearman and Kärber 
 
The titration of measles vaccine virus was performed by Dr. Martina Schell. 
 Microscopy 
Before plating and on the infection day, cells were observed at various 
magnifications with a light microscope to check for contamination, cell 
distribution and confluence. During trials, virus-encoded GFP and TurboFP635 
expression were visualized several times under a fluorescence microscope with 
suitable excitation and emission wavelengths, or observed constantly in a 
separate trial (section 3.5.2) using the All-in-One BZ-9000 fluorescence 
microscope.  
A high-definition camera (F-view, Soft Imaging System GmbH) was connected 
to the microscope (IX50, Olympus) to take fluorescence pictures by applying the 
Olympus U-RFL-T function. Bright-field pictures were taken with a 4–10 x 
objective with the PhL, respectively the Ph1/PhC ocular. Captured images were 
processed with the Analysis 3.1 software (Soft Imaging System GmbH) and 
merged to yield overlays by Adobe Photoshop 7.0 (Adobe Systems, Mountain 
View, CA). Digital images (All-in-one BZ-9000 fluorescence microscope) were 
further processed with the BZ-II software. Here, haze reduction, black balance 
and the superimposing function were applied in order to receive sharp-cut 




images. All images were adjusted with Microsoft PowerPoint 2010, respectively 
Microsoft PowerPoint 2013. 
 Determination of cell mass and cytotoxic effects 
After incubation with oncolytic viruses, we needed to quantify the cytotoxic 
effect of virus infection. Therefore, Sulforhodamine-B (SRB) assay (Skehan et 
al, 1990) was performed. The SRB assay measures the residual cell mass, but 
it does not differentiate between viable and dead cells (Vichai & Kirtikara, 2006). 
Therefore, results obtained by SRB were compared to those of MTT, a cell 
viability assay.  
2.2.6.1 SRB assay 
The SRB assay uses the characteristics of Sulforhodamine-B as an acid dye for 
cell staining. Thus, the remaining cell mass can be quantified in drug-toxicity 
trials. SRB binds to cellular proteins when cells were fixed with TCA or 
comparable acids before. After dissolution under mild basic conditions, the 
optical density (OD) is measured by using a microtiter plate reader (Tecan 
GENios). The OD correlates linear with the protein content and therefore with 
the remaining cell count (Skehan et al, 1990).  
The exact procedure includes the following steps. Medium was removed from 
the wells at 96 hpi the longest and cells were washed with cold (4 °C) PBS. 
Thereafter, cells were fixed with 250 µl cold (4 °C) TCA (10 % w/v) per well. 
Plates were incubated at 4 °C for at least 30 minutes. After this time period, 
TCA was removed and discarded, plates were washed three times with tap 
water, before dried under UV light for approximate 15 minutes. Subsequently, 
plates were stored in a heating cabinet (40 °C) for at least 12 hrs or overnight to 
ensure the drying process.  
In a next step, SRB dye and 1 % acetic acid needed to be prepared. 250 µl of 
room-tempered SRB dye/well were added to the cells and incubated for 
10 minutes. Thereafter, plates were washed accurately with 1 % acetic acid 
until no unbound staining solution remained. To double-check, plates were 




tapped firmly on absorbent paper. Next, plates were ranged in the heating 
cabinet (40 °C) until they were dried completely and either measured directly or 
stored in a dark place for a couple of days. 
For the measurement of OD at 550 nm, 500 or 1000 µl/well TRIS base (10 mM, 
pH 10.5), depending on the colour intensity, were pipetted to the cells. Plates 
were stored on ice and agitated gently until the stain was dissolved completely. 
Subsequently, 80 µl/well in duplicates were transferred into a 96-well plate 
consistent with a microtiter plate reader. Results were further calculated with 
Microsoft Excel 2010. The following statistical analysis was performed with 
GraphPad Prism4 and GraphPad Prism6 (GraphPad Software). Values of 
treated cells were normalized on mock-treated cell data (set as 100 %) unless 
otherwise specified.  
2.2.6.2 MTT assay 
As another colorimetric assay, the MTT assay quantifies cell metabolic activity 
and therefore cell viability. Only viable cells convert 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, a pale yellow tetrazolium salt, into blue 
colored formazan crystals. The OD, measured by a microtiter plate reader, is 
directly proportional to the amount of living cells (Mosmann, 1983).  
First, MTT stock solution needed to be prepared and protected from light, thus, 
the tube was wrapped with aluminum foil at any time. After various incubation 
periods with oncolytic viruses, plates were washed carefully with PBS. Next, 
250 µl MTT solution/well were added for 2 hrs at 37 °C. Thereafter, the 
supernatant was aspirated carefully and discarded. Plates were wrapped 
quickly with a strip of parafilm and stored in the refrigerator at -20 °C. For 
measurement, 1 ml of acidified isopropanol (1 N HCl in isopropanol) was added 
to each well and plates were placed on a shaker until the dye dissolved 
thoroughly. Next, 200 µl of each well were transferred to a 96-well plate 
consistent with a microtiter plate reader. Measurement was now performed 
using a 570 nm test wavelength and a 650 nm reference wavelength. The 
received data was calculated with Microsoft Excel 2010 and Microsoft Excel 




2013. The following statistical analysis was performed with GraphPad Prism4 
and GraphPad Prism6 (GraphPad Software).  
 Polyacrylamide gel electrophoresis (PAGE) and western blot 
2.2.7.1 Production of protein lysates 
Cells were plated in 24-well plates and incubated overnight as described before. 
The next day, wells were either infected by VACV at defined MOIs in 50 µl/well 
2 % FBS-supplemented DMEM, or cells were mock-treated. Thereafter, plates 
were sequentially infected at 6 hpi with MeV-GFP. At the end of the incubation 
period, supernatant was removed and wells were washed carefully with PBS. 
PBS was not discarded but pooled to reduce cell loss due to this washing step. 
Next, 125 µl EDTA-Trypsin/well were applied for the detachment of the cell 
layer. Identically treated cells were now collected in tubes. Wells were washed 
with 500 µl 10 % FBS-supplemented DMEM and the volume was transferred to 
the belonging tube to inactivate the EDTA-Trypsin. PBS and collected cells 
were merged, before tubes were centrifuged at 1200 rpm for 3 minutes at 
22 °C. In the meantime, the prepared lysis buffer was completed by adding one 
tablet complete mini, a protease inhibitor. Accordingly, supernatant was 
discarded from the centrifuged tubes, 450 µl of the finished lysis buffer were 
pipetted to each cell pellet and resuspended thoroughly, before the tubes were 
sonicated 3 x 30 seconds. Subsequently, the obtained protein lysates were 
centrifuged at 4600 rpm for 10 minutes at 4 °C. The supernatant was aspirated 
and distributed to the prepared reaction tubes, 150 µl per tube. Lysates were 
then stored at -20 °C.  
2.2.7.2 Discontinuous SDS-Polyacrylamide gel electrophoresis 
Electrophoresis, a method to investigate the mobility of macromolecules in an 
electric field, is widely used to categorize proteins according to their size, 
confirmation and charge. By using Sodium-Dodecyl-Sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE), proteins are separated exclusively according to 
their size. 2-mercaptoethanol and SDS are attached to linearize proteins, SDS 




additionally charges polypeptides equally negative dependent on their 
molecular weight. In order to sharpen bands, a discontinuous SDS-PAGE 
(Laemmli, 1970), containing a 1.5 mm stacking gel with 5 % acrylamide and a 
resolving gradient gel with 8 to 15 % acrylamide, was performed.  
First, the gel caster was assembled and the resolving gradient gel was 
compounded using 8 % and 15 % resolving gel solutions. APS and TEMED 
were added at last because they start the polymerization. Approximately 10 ml 
of both approaches (8 and 15 % resolving gel solutions) were poured between 
the two glass plates using a pulsatile pump, which is necessary to provide a 
controlled mixture. Next, 1 ml isopropanol was pipetted on top to flatten the gel. 
After the resolving gel was polymerized, isopropanol remnants were outpoured 
and the gel was overlaid with the prepared stacking gel. Before the stacking gel 
was polymerized completely, a 15-pocket comb was inserted.  
Prior to use, the loading buffer was adjusted by adding 2-mercaptoethanol to 
cleave disulfide bonds. Now, an appropriate volume of each protein lysate was 
transferred to 1.5 ml reaction tubes. Subsequently, a calculated volume of the 
loading buffer (1/5 of the volume of each protein lysate) was added to each 
sample, and lysates were stored on ice or at -20 °C. Now, the loaded lysates 
were centrifuged at 13000 rpm for 1 minute, denatured at 95 °C for 10 minutes 
and once again centrifuged. Tubes were stored on ice before reaching room-
temperature.  
The gel cassette was now placed in a vertical electrophoresis chamber, which 
was filled with PAGE buffer (1 x). The inserted comb was removed carefully and 
the remaining cavities were flushed out with PAGE buffer (1 x). Each sample 
was pipetted at a defined volume into the slots. The first slot was reserved for 
the rainbow marker (Full Range Rainbow Protein Marker), which was used as 
molecular weight standard. All filled slots were covered with a small layer of 
PAGE buffer (1 x). Now, the assembly of the electrophoresis chamber was 
completed and the tank was filled up with PAGE buffer (1 x) to the rim. 
Electrophoresis was started at a higher voltage (100 V) for 30 minutes. 




Thereafter, 55 V were applied overnight until the bromophenol blue front 
reached the edge of the resolving gel. 
2.2.7.3 Western Blot 
To visualize macromolecules, separated by discontinuous SDS-PAGE, proteins 
were transferred from the resolving gel to a membrane by blotting technique 
and afterwards detected by linked antibodies (Burnette, 1981; Towbin et al, 
1992). 
A PVDF membrane, which is often preferred when compared to nitrocellulose 
membranes (Mahmood & Yang, 2012), was slewed in methanol, rinsed with 
filtered water (H2Odd) and incubated with transfer buffer (1 x) on a shaker for 
15 minutes. Additionally, two sponges and three Whatman papers, which are 
necessary to assemble the blot sandwich, were soaked in transfer buffer (1 x). 
The glass plates of the gel caster (section 2.2.7.2) were removed carefully and 
the stacking gel was separated from the resolving section. Next, the resolving 
gel was placed upon the prepared membrane, air bubbles were prevented by 
the aid of a glass rod. Covered by transfer buffer (1 x), the blot sandwich was 
assembled and fixed accurately in a suitable blotting system. Blotting was 
performed at 400 mA for 90 minutes at 4 °C. Since the membrane was oriented 
in direction of the anode, negative loaded proteins were transferred to the 
membrane.  
After blotting, unspecific binding of antibodies was prohibited by blocking the 
PVDF membrane with 5 % milk in TBS-Tween (2.5 g milk powder, resolved in 
50 ml TBS-Tween) for at least 90 minutes. Thereafter, the membrane was 
rinsed thoroughly with TBS-Tween for 5 minutes, wrapped in transparent film 
and cut into various pieces dependent on the expected positions of the bands. 
The visible rainbow marker served as a landmark, since each coloured line of 
the marker stands for a specific molecular weight. 
Next, antibody solutions were diluted as detailed in section 2.1.2. Primary 
antibodies were incubated with their belonging pieces of the PVDF membrane 
on a shaker at 4 °C overnight. The following day, diluted antibody solutions 




were recycled and the pieces of the membrane were washed 3 x 10 minutes 
with TBS-Tween to remove unstable bounded antibodies. For binding of 
secondary antibodies, directed against mouse IgG or rabbit IgG, matching 
pieces were incubated at room-temperature for 45 minutes under gentle 
agitation.  
The secondary antibody is linked to an enzyme called horseradish peroxidase 
(HRP). This enzyme converts ECL solution, which contains luminol, under basic 
conditions into a reaction product generating luminescence. The light intensity, 
which is dependent on the amount of bound protein, exposes and develops an 
X-ray film (HyperfilmTM ECL), and thereby visualizes the antibody-linked 
proteins on the membrane.  
Accordingly, after incubation with the secondary antibody, the pieces were 
rinsed 4 x 15 minutes with TBS-Tween. By avoiding air-bubbles, detection 
reagent 1 and 2 of the ECL solution were mixed at equal volumes and 
incubated with the pieces for 1 minute. Thereafter, the pieces were fixed in a 
photo cassette and exposed to a sensitive photo film (Fuji Photo Film).  
For detection of proteins with similar molecular weights, it was necessary to 
remove the linked primary and secondary antibodies. In order to do so, the 
pieces of the membrane were incubated for 30 minutes at 50 °C with a stripping 
buffer, washed 6 x 10 minutes with TBS-Tween and blocked with 5 % milk in 
TBS-Tween as described above. The detection process was then repeated with 
the application of the suitable primary antibody. 
  






The aim of this thesis was to test a novel approach for overcoming resistance of 
tumor cells against virotherapy by performing sequential infections applying two 
completely different virus types, i.e., oncolytic vaccinia virus together with 
measles vaccine virus. 
Accordingly, preliminary tests with both viral vectors were performed to 
determine “appropriate” multiplicities of infection (MOIs), defined as viral 
concentrations at which the tumor cell mass was reduced less than 25 % in a 
single infection approach. Thus, highly resistant human tumor cell lines, such as 
ACHN, HCT15, KM12, SRH and CCS, were seeded at equal plating density 
and infected first with oncolytic VACV GLV-1h254 at various MOIs (section 
3.1.1). 
Based on the observation that each tumor cell line required different plating 
densities to reach confluence, we compared several initial cell counts to identify 
the most suitable one (section 3.1.2.1). As a proof of principle, xCELLigence 
trials with ACHN and KM12 cells were performed (section 3.1.2.2). Single 
infection approaches with VACV were repeated at confluence-optimized plated 
cells (section 3.1.3) and executed with MeV-GFP for the first time (section 
3.1.4).  
In order to guarantee survival of untreated cells until the end of the trial, single 
infection approaches with VACV were modified and repeated for ACHN, HCT15 
and KM12 cells (section 3.1.5). Eventually, we were able to examine different 
orders of virus treatment and different time points for secondary virus infection 
in sequential infection approaches (section 3.2). To further investigate whether 
an improved susceptibility to virus infection of double-infected cells was due to 
synergistic or additive effects, we performed sequential infections at different 
dosages of the second virus (section 3.3).  
In addition, a Keyence microscope was implemented to get a closer look at the 





obtained from SRB assays were compared to those from MTT assay to confirm 
the results and detect potential sources of error (section 3.4). 
Finally, electrophoresis and western blot were implemented to investigate the 
expression of virus-specific proteins (section 3.6).  
3.1 Identification of a suitable MOI for both viral vectors by single 
infections 
The resistance of human tumor cell lines such as ACHN, HCT15, KM12, SRH 
and CCS upon virotherapy is relative. Here, highly resistant cell lines were 
defined by cell mass reduction of less than 25 % compared to uninfected 
controls at 96 hpi. In order to determine an appropriate MOI, single virus 
infections were performed with both viral vectors. Prior to infection trials, 
vaccinia and measles vaccine virus titers were determined according to the 
methods described in section 2.2.4.4.  
 Preliminary tests for vaccinia virus GLV-1h254 infection 
As suggested in previous work from C. Raff (unpublished data) and M. Noll 
(Noll et al, 2013), all three selected cell lines of the NCI-60 panel (ACHN, 
HCT15 and KM12) as well as a sarcoma (CCS) and a rhabdomyosarcoma 
(SRH) cell line were seeded equally in 24-well plates. Cells were incubated 
overnight and 5 x 104 cells/well were assumed to comply with current cell 
counts. On the infection day, cells were either infected in quadruplicates with 
VACV GLV-1h254 at MOI 0.0001, 0.001, 0.01, 0.1 and 1 or mock-treated. 
During the incubation period, expression of virus-encoded TurboFP635 was 
observed daily under a fluorescence microscope (Figure 9). At 96 hpi, plates 
were analyzed by SRB assay (Figure 10).   
 
As visualized in Figure 9, we noticed differences between the cell lines referring 
their reached extent of confluence one day post infection (1 dpi). Whereas 
ACHN cells grew subconfluent, and HCT15 cells reached approximately 50 % 
confluence, KM12, SRH and CCS cells revealed a slower growth behavior. For 
CCS cells there were no pictures archived at 1 dpi. 








Figure 9. Overlays of fluorescence and bright-field pictures from VACV single-infected 
human tumor cell lines, 1 dpi 
Cells were seeded at equal plating densities (5 x 104 cells/well in 24-well plates). Cells were 
either infected with VACV GLV-1h254 at MOI 0.0001, 0.001, 0.01, 0.1 and 1 or mock-treated. 
Fluorescence and bright-field pictures were taken at 1 dpi and overlaid afterwards. Infected cells 
show TurboFP635 expression as VACV marker for viral gene expression (HCT15 at 
MOI 0.0001: red signal is based on an artifact). Scale bar in the right lower corner applies to all 
panels. 
  
As detailed in Figure 10, ACHN and HCT15 cells were defined highly resistant 
at MOI 0.01, according to the specification given above, when analyzed by SRB 
assay. At higher MOIs cell masses were reduced more than 25 %. For KM12, 
SRH and CCS cells it was difficult to make a statement because of large 
standard deviations of means of three independent experiments. As a 
consequence, the development of confluence dependent on plating densities 




































































































































































































































Figure 10. Identification of a suitable MOI in equally plated tumor cell lines infected with 
VACV GLV-1h254 in SRB assays 
Cells were plated at 5 x 104 cells/well. The next day (except CCS: one data set was obtained 
from cells infected 2 days after plating), cells were either infected in quadruplicates with VACV 
at MOI 0.0001, 0.001, 0.01, 0.1 and 1 or mock-treated. At 96 hpi, cells were fixed and the 
remaining cell mass was analyzed by SRB assay. Mock-treated (uninfected) controls were set 
100 %. Dotted lines highlight the 50 and 75 % remaining cell mass. Values are means of three 
independent experiments (except ACHN: Values until MOI 0.1 are means of four independent 








 Evaluation of cell density and confluence 
To guarantee optimal conditions for uninhibited cell growth, as well as for virus 
infection and spreading, the development of confluence was analyzed. Thus, so 
called “confluence trials” were performed for each cell line. Additionally, a proof 
of principle was generated by xCELLigence trials using ACHN and KM12 cells.  
3.1.2.1 Confluence trials 
We evaluated the development of confluence, dependent on several plating 
densities, and studied cell adherence and growth rate. Furthermore, we took 
note of medium color change. ACHN, HCT15, KM12, SRH and CCS cells were 
plated at densities of 5 x 104, 1 x 105 and 2 x 105 (except SRH) cells/well in 24-
well plates. KM12 cells were additionally seeded at 4 x 105 cells per well. Cells 
were incubated for 6 days and observed daily under a light microscope. The 
reached extent of confluence was documented, expressed as an estimated 
percentage (Figure 11). 
At a plating density of 5 x 104 cells/well, ACHN cells adhered overnight and 
reached approximately 50 % confluence within two days. At this plating density, 
HCT15 and CCS cells stuck to the bottom not until two days after plating. At a 
density of 1 x 105 cells/well, ACHN, HCT15 and SRH cells reached a plateau at 
day 4 (ACHN, HCT15), respectively at day 3 (SRH). At day 5, ACHN and 
HCT15 cells showed medium color change from red to yellow, which indicated 
reduced pH values. CCS and KM12 cells, however, adhered insufficiently to the 
bottom and tended to detach at higher densities although cells did not reach 
total confluence. Additionally, KM12 cells agglomerated quickly and 
independent of the initial cell count and the medium color turned yellow at day 4 
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Figure 11. Extent of confluence during 6 days of incubation 
ACHN, HCT15, KM12, SRH and CCS cells were plated at 5 x 104, 1 x 105 and 2 x 105 (except 
SRH) cells/well in 24-well plates. KM12 cells were additionally seeded at 4 x 105 cells/well. Cell 
lines were examined under a light microscope for six days and evaluated by the naked eye. The 
extent of confluence related to initial cell counts is diagrammed (expressed as a percentage). 
Dotted lines highlight 50 and 100 % confluence of the cell layer.  
 
Accordingly, initial cell counts were retrospectively determined for each cell line 
in order to optimize survival of uninfected controls until 96 hpi. Unless otherwise 










Table 1. Recommended plating densities for each cell line to build optimal confluence in 
24-well plates 
The table shows the recommended number of days before infection and plating densities at 
which cells should be plated in 24-well plates. dbi = days before infection. 
Cell line Days before infection (dbi), plating densities 
ACHN 1 dbi, 5 x 104 cells/well 
HCT15 2 dbi, 5 x 104 cells/well 
KM12 2 dbi, 4 x 105 cells/well 
SRH 2 dbi, 5 x 104 cells/well 
CCS 2 dbi, 2 x 105 cells/well 
  
3.1.2.2 xCELLigence trial 
Confluence trials, as depicted in section 2.2.3.3, were necessary to determine 
suitable initial cell counts in 24-well plates. Nevertheless, the development of 
confluence was evaluated by the naked eye only. Consequently, cells were 
further analyzed by xCELLigence system to demonstrate a proof of principle. If 
the plating density is chosen too high, uninfected controls will grow over, which 
induces growth inhibition and cell death. Additionally, the initial cell count, and 
therefore the extent of confluence, affects efficiency of infection and spreading 
of vaccinia virus particles.  
Prior to xCELLigence trial, initial cell counts suitable for 96-well plates needed 
to be identified. Thus, several plating densities (1 x 105, 5 x 104, 2.5 x 104, 1 x 
104, 5 x 103, 2.5 x 103 and 1 x 103 cells/well) of ACHN and KM12 cells were 
seeded in 96-well plates, and cells thereafter infected with VACV GLV-1h254 at 
MOI 0.1, 1 or mock-treated. Virus spreading and the development of confluence 
were monitored under a fluorescence microscope until 96 hpi.  
As a result, ACHN cells were plated at 1 x 103, 2 x 103, 4 x 103 and 8 x 103 
cells/well, KM12 cells at 2.5 x 103, 5 x 103, 1 x 104, 2 x 104 cells/well in the 
following xCELLigence trial. After 22.5 hrs, cells were infected with VACV GLV-
1h254 at MOI 0.1, 1 or mock-treated. Triton 0.1 % X-100 was used as a positive 




control for cell death. Electrical impedance was measured at 30-minute intervals 
and all curves were normalized. Unfortunately, KM12 cells did not adhere firmly 
enough; thus, electrical impedance could not be measured sufficiently and 
values were neglected. 
As shown in Figure 12, uninfected controls of ACHN cells plated at low 
densities did still proliferate at 96 hpi. However, mock-treated cells, which were 
seeded at higher cell numbers, hit a plateau (4 x 103 cells/well 90 hpi) or even 
levelled off (8 x 103 cells/well 60 hpi). Interestingly, with higher cell numbers the 
disparity of the normalized cell index between mock treated and virus infected 
cells increased. In particular, this was evident for the MOI 0.1 treatment group. 
The xCELLigence trial was kindly supported by Dr. Dr. Sascha Venturelli, 







Figure 12. xCELLigence in real-time monitoring of cell proliferation 
ACHN cells were plated in triplicates at densities of 1 x 103, 2 x 103, 4 x 103 and 
8 x 103 cells/well. At 22.5 hrs after seeding, cells were either infected with VACV GLV-1h254 
MOI 0.1, 1 or mock-treated. Triton X-100 0.1 % was used as positive control for cell death. Cell 
index was continuously monitored in 30-minute intervals, starting after plating the cells. All 
values were normalized (line mark). Error bars: SD. This figure was kindly generated by Dr. Dr. 
Sascha Venturelli.  
 




 Identification of a suitable MOI for vaccinia virus GLV-1h254 in 
confluence-optimized plated cells 
As specified above, appropriate MOIs should be determined by infection of 
confluence-optimized plated cells. Thus, HCT15, KM12, SRH and CCS cells 
were seeded as detailed in Table 1. Due to the fact that test conditions for 
ACHN cells did not changed, approaches were not repeated for this cell line.  
On the infection day, cells were inoculated in quadruplicates with VACV at 
MOI 0.0001, 0.001, 0.01 and 0.1 or mock-treated. MOI 1 was no longer applied, 
since cell masses of infected cells were eradicated completely in preliminary 
tests (section 3.1.1). During the incubation period, cells were observed daily 
under a fluorescence microscope. At 96 hpi, cells were fixed and analyzed by 
SRB assay (plates were washed once with tap water before washed 
approximately three times with 1 % acetic acid).  
As shown in Figure 13, virus infection and spreading were monitored by 
observation of virus-encoded TurboFP635. As assumed, the number of infected 
cells increased at ascending viral concentrations and led to plaque forming units 
(HCT15, CCS). Interestingly, although GLV-1h254 formed large plaque forming 
units at MOI 0.01 and 0.1 in HCT15 cells, analysis by SRB assay revealed less 
cell mass reduction than expected (Figure 14). KM12, SRH and CCS cells were 


















Figure 13. Overlays of fluorescence and bright-field pictures from VACV single-infected 
human tumor cell lines, confluence-optimized, 4 dpi  
HCT15, KM12, SRH and CCS cells, seeded at confluence-optimized plating densities (Table 1), 
were either single-infected with VACV GLV-1h254 at MOI 0.0001, 0.001, 0.01, 0.1 or mock-
treated. Fluorescence and bright-field pictures were taken at 4 dpi and overlaid afterwards. 
Infected cells show TurboFP635 expression as VACV marker for viral gene expression. Scale 
bar in the right lower corner applies to all panels.  
 
As represented in Figure 14, HCT15 and KM12 cells were defined highly 
resistant at MOI 0.01. At MOI 0.1, however, cell counts were decreased to the 
critical value of 75 % (HCT15) or even lower (KM12). SRH and CCS cells were 
erased almost completely at ascending viral concentrations (MOI 0.01, 0.1). 
When compared to results obtained from SRB assay in section 3.1.1, here, 
means of KM12 cells show lower standard deviations, whereas those of SRH 
and CCS were unimproved. Anyhow, cell masses from SRH and CCS cells 
infected at MOI 0.001, 0.01 and 0.1 were reduced compared to those obtained 
from equally plated cells (Figure 10). Resulting, SRH and CCS cells were 
defined as resistant at MOI 0.0001 according to the definition given above. 
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Figure 14. Identification of a suitable MOI in confluence-optimized plated cell lines 
infected with VACV GLV-1h254 in SRB assays  
Cells were plated as detailed in Table 1. Cells were either infected in quadruplicates with VACV 
at MOI 0.0001, 0.001, 0.01 and 0.1 or mock-treated. At 96 hpi, cells were fixed and the 
remaining cell mass was analyzed by SRB assay. Mock-treated (uninfected) controls were set 
100 %. Dotted lines highlight the 50 and 75 % remaining cell mass. Values are means of three 
independent experiments. Error bars: SD. 
 
 Identification of a suitable MOI for measles vaccine virus MeV-GFP in 
confluence-optimized plated cells  
All five cell lines were seeded according to Table 1 and infected in 
quadruplicates at ascending viral concentrations (MOI 0.001, 0.01, 0.1, 1 and 
10) with MeV-GFP or were mock-treated. Cells were incubated until 96 hpi and 
virus-encoded GFP was observed daily under a fluorescence microscope. At 
96 hpi, infected cells were analyzed via endpoint SRB assay (plates were 
washed once with tap water before washed approximately three times with 1 % 





The number of infected cells, visualized by virus-encoded GFP expression and 
syncytia formation, increased at ascending viral concentrations in all cell lines, 
except for SRH cells where only few infected cells could be visualized 
(Figure 15). At MOI 10, HCT15 cells were barely infected, whereas ACHN, 





Figure 15. Overlays of fluorescence and bright-field pictures from MeV-GFP single-
infected human tumor cell lines, confluence-optimized, 4 dpi 
ACHN, HCT15, KM12, SRH and CCS cells, seeded at confluence-optimized plating densities 
(Table 1), were either single-infected with MeV-GFP at MOI 0.001, 0.01, 0.1, 1, 10 or mock-
treated. Fluorescence and bright-field pictures were taken separately at 4 dpi and overlaid 
afterwards. Infected cells show GFP expression as marker for viral gene expression and 
syncytia formation as cytopathic effect. Scale bar in the right lower corner applies to all panels.  
 
 
When ACHN, HCT15, KM12, SRH and CCS cells were analyzed by SRB assay 
regarding oncolysis (Figure 16), these cell lines responded barely to virus 
infections at MOI 0.001, 0.01 or 0.1. At MOI 1, ACHN, SRH and CCS cells 
showed a cell mass reduction but less than 25 %, whereas HCT15 and KM12 
cells showed almost no tumor cell lysis. It has to be mentioned that cell counts 
of SRH and CCS cells revealed large standard deviations between three 
800 µm 




independent experiments. At MOI 10, ACHN cells were reduced to nearly 50 %, 
HCT15 and SRH cells showed an increased cytopathic effect above the critical 
value of 75 % but with large standard deviations.  
Cell numbers of KM12 and CCS cells, however, collapsed almost completely at 
the highest MOI. Consequently, MOI 1 was defined as the critical multiplicity of 
infection for MeV-GFP for further experiments concerning ACHN, HCT15 and 
KM12 cells. 
 













































































































































































































ACHN, HCT15, KM12, SRH and CCS cells were plated as described in Table 1, and infected in 
quadruplicates with MeV-GFP at MOI 0.001, 0.01, 0.1, 1 and 10 or mock-treated. At 96 hpi, 
cells were fixed and the remaining cell mass was analyzed by SRB assay. Uninfected controls 
were set 100 %. Dotted lines highlight the 50 and 75 % remaining cell mass. Values are means 
of three independent experiments. Error bars: SD. 
 Identification of a critical MOI for vaccinia virus (GLV-1h254) - plotted as 
relative to mock and relative to 0 hrs of infection 
As detailed in section 3.1.3, critical MOIs for vaccinia virus were identified by 
infection of confluence-optimized plated cells. As cell indices of infected cells 
were related to those of uninfected controls, it was essential to guarantee cell 
survival of mock-treated cells at 96 hpi. Until now, we were unable to ensure the 
survival of controls, since plating densities were recommended on data which 
were collected with the naked eye only (section 3.1.2.1). 
Here, single infection approaches with VACV were modified in order to evaluate 
growth characteristics of ACHN, HCT15 and KM12 cells from day to day by 
SRB assay and fluorescence microscopy. We focused on ACHN, HCT15 and 
KM12 cells in all further experiments, since these cell lines were resistant to 
VACV single infection at higher MOIs in contrast to SRH and CCS cells (section 
3.1.3).  
ACHN and HCT15 cells were plated according to recommended initial cell 
counts, listed in Table 1, in 24-well plates. KM12 cells were seeded at several 
densities (5 x 104, 1 x 105 and 2 x 105 cells/well). Cells were incubated overnight 
(ACHN), respectively for two nights (HCT15, KM12). One plate of each cell line 
was fixed prior to infection to obtain an output value (0 hpi). Adhered ACHN, 
HCT15 and KM12 cells (plated at 5 x 104 and 2 x 105 cells/well) were either 
infected with VACV GLV-1h254 in quadruplicates at MOI 0.001, 0.01, 0.05, 0.1 
and 0.5 or mock-treated. KM12 cells plated at 1 x 105 cells/well were either 
infected at MOI 0.001, 0.005, 0.01, 0.05 and 0.1 or mock-treated. Here, MOIs 
were adjusted to obtain the possibility to survey differences between treatment 
groups reliant on minor alterations of virus concentration. At 1.5 hpi, 200 µl 
22 % FBS-supplemented DMEM were added to the wells. Plates were 
incubated for 24, 48, 72 or 96 hpi.  




Virus-encoded TurboFP635 expression was monitored under a fluorescence 
microscope, pictures (Figure 17) were taken prior to analysis by SRB assay. 
Values were plotted either as relative to 0 hrs or as relative to mock at 96 hpi.  
 
As visualized in Figure 17, virus infection and spreading were monitored daily. 
At ascending viral concentrations and days post infection, the number of 
infected cells increased in all cell lines and the characteristic formation of virus 
plaques was detected (ACHN (A), HCT15 (B)). For KM12 (C-E), it became 
obvious that cells agglomerated quickly at all seeding densities. As a 
consequence, for this cell line total confluence was impossible to reach, as 
described before. Additionally, from 2 dpi on, mock-treated KM12 cells 
























Figure 17. Overlays of fluorescence and bright-field pictures from VACV single-infected 
human tumor cell lines, confluence-optimized, 1-4 dpi 
Cells were infected with VACV at MOI 0.001, 0.01, 0.05, 0.1 and 0.5 (ACHN (A), HCT15 (B), 
KM12 plated at 5 x 104 (C) and 2 x 105 cells/well (E)), respectively at MOI 0.001, 0.005, 0.01, 
0.05 and 0.1 (KM12 plated at 1 x 105 cells/well) (D) or mock-treated. Fluorescence and bright-
field pictures were taken every day (1-4 dpi) and overlaid afterwards. Infected cells show 
TurboFP635 expression as VACV marker for viral gene expression and plaque formation. Scale 
bar in the right lower corner applies to all panels.  
 
The corresponding analysis of the treated cells by SRB viability assay revealed 
that mock-treated controls of ACHN and HCT15 cells still proliferated at 96 hpi 








hit a plateau when plated at 5 x 104 (at 96 hpi) and 1 x 105 cells/well (at 72 hpi) 
or even leveled off (2 x 105 cells/well at 96 hpi). It has to be noted that results 
from KM12 cells were either means of three independent experiments (1 x 105 
cells/well) or of two experiments (2 x 105 cells/well), respectively one data set (5 
x 105 cells/well). As a result, recommended plating densities for ACHN and 
HCT15 cells (Table 1) were maintained. For KM12 cells, 1 x 105 cells/well was 
chosen as new plating density. 
As expressed in Figure 18 on the right, MOI 0.01 was verified as suitable value 
in single infection approaches for ACHN and HCT15 cells, whereas MOI 0.005 


















Figure 18. Identification of a suitable MOI for each cell line infected with VACV GLV-
1h254 in SRB assays, blotted relative to 0 hrs and relative to mock 
Cells were infected in quadruplicates with VACV at MOI 0.001, 0.01, 0.05, 0.1 and 0.5 (ACHN 
(A), HCT15 (B), KM12 plated at 5 x 104 (C) and 2 x 105 cells/well (E)), respectively at MOI 0.001, 
0.005, 0.01, 0.05 and 0.1 (KM12 plated at 1 x 105 cells/well) (D) or mock-treated. At 0, 24, 48, 
72 and 96 hpi, cells were fixed and the remaining cell mass was analyzed by SRB assay. 
Values were either plotted as relative to 0 hrs (on the left), or as relative to mock 96 hpi (on the 
right) with uninfected controls set 100 %. Dotted lines highlight the 50 and 75 % remaining cell 
mass on the right. Values are means of three independent experiments (except KM12 plated at 
5 x 104 cells/well: means of one experiment, plated at 2 x 105 cells/well: means of two 








3.2 Double infection trials 
After threshold MOIs were determined successfully in single infection 
approaches for both viral vectors, application schemes for double infection trials 
were established.  
Here, different orders of viruses, time points of secondary virus infection and 
multiplicities of infection were investigated in order to identify the most effective 
application scheme. Accordingly, ACHN, HCT15 and KM12 cells were seeded 
at adapted plating densities and incubation periods (Table 2). 
 
Table 2. Adapted plating densities for ACHN, HCT15 and KM12 cells in 24-well plates 
The table shows the adapted and recommended number of days and plating densities at which 
tumor cells were plated in 24-well plates prior to infection. 
Cell line Days before infection (dbi), plating densities 
ACHN 1 dbi, 5 x 104 cells/well 
HCT15 2 dbi, 5 x 104 cells/well 
KM12 2 dbi, 1 x 105 cells/well 
 
 Combinatorial treatment - VACV infection prior to infection with MeV 
ACHN, HCT15 and KM12 cells were either infected by VACV GLV-1h254, as 
detailed in section 3.1.5, without application of the highest MOI (0.5 for ACHN 
and HCT15, 0.1 for KM12), or mock-treated.  
At 2, 6 or 12 hpi, cells were either double-infected by MeV-GFP at MOI 1 or 
medium was added to mock-treated and single-infected wells. MeV-GFP single-
infected controls were executed for each time point (2, 6, 12 hpi). Additionally, 
another plate was single-infected by VACV and MeV-GFP to generate single-
infected controls at 0 hrs.  
The expression of virus-encoded marker genes GFP and TurboFP635 was 





infection with the first virus), cells were fixed and analyzed by SRB assay. 




Figure 19. Application scheme for double-infections, VACV GLV-1h254 prior to MeV-GFP 
Cells were plated in 24-well plates 1 dbi (ACHN), respectively 2 dbi (HCT15 and KM12 cells). 
On the infection day, cells were inoculated in quadruplicates with VACV GLV-1h254 at 
ascending MOIs from 0.001 to 0.05 (KM12), respectively 0.001 to 0.1 (ACHN, HCT15),  
1-2 dbi “0 h“
+ VACV GLV-1h254 MOI 0.001 – MOI 0.1
12 hpi2 hpi 6 hpi
+ MeV GFP MOI 1
96 hpi
plating of cells end of treatment+ FCS
1-2 dbi “0 h“
+ VACV GLV-1h254 MOI 0.001 – MOI 0.1
12 hpi2 hpi 6 hpi
+ MeV GFP MOI 1
96 hpi
plating of cells end of treatment+ FCS
1-2 dbi “0 h“
+ VACV GLV-1h254 MOI 0.001 – MOI 0.1
12 hpi2 hpi 6 hpi
+ MeV GFP MOI 1
96 hpi








or mock-treated. Secondary virus infection with MeV-GFP at MOI 1 took place at 2 (A), 6 (B) or 
12 hpi (C) with the first virus. At each time point (0, 2, 6, 12 hpi), single virus infections with 
MeV-GFP were performed as controls (not shown). Plates were incubated until 96 hpi with the 
first virus. The remaining cell mass was measured by SRB assay.  
 
Infected cells were visualized by vaccinia virus-encoded TurboFP635 and 
measles vaccine virus-encoded GFP expression (Figure 21). Additionally, the 
resulting cytopathic effect, demonstrated by plaque formation and syncytia 
building, was observed in bright-field microscopy.  
At ascending viral concentrations the number of infected cells increased in all 
cell lines (ACHN, HCT15 and KM12). Major differences between the time points 
of infection with the second virus (2, 6 or 12 hpi with MeV) were not perceived.  
However, we made a peculiar observation concerning combinatorial treated 
cells: 
Exemplified by ACHN cells infected at MOI 0.001 (VACV), followed by 
inoculation with MeV-GFP at MOI 1 (at 2 hpi), we noticed that most of the cells 
were infected “only” in a singular manner, either by VACV or by MeV-GFP 
(Figure 20). 
 When VACV was applied at a low MOI (0.001), the majority of the cells was 
infected by the second virus, i.e. MeV-GFP, and consequently expressed 
primarily the GFP marker protein.  
 When compared to double-treated ACHN cells at higher MOIs (0.01, 0.05, 
0.1 of VACV), it was just the other way round. Now, most of the cells 
expressed the TurboFP635 marker protein. 











Figure 20. Fluorescence and bright-field pictures from combinatorial infected ACHN 
cells, VACV GLV-1h254 prior to MeV-GFP at 2 hpi. Selection of Figure 21 
A 
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ACHN cells were seeded in 24-well plates and either infected by VACV at MOI 0.001 (A) or 
MOI 0.1 (B), respectively. At 2 hpi, cells were additionally inoculated with MeV-GFP at MOI 1. At 
4 dpi, fluorescence (TurboFP635, GFP) and bright-field (BF) pictures were taken using Olympus 
IX50 fluorescence microscope. The image in the bottom right corner shows the overlay of both 
fluorescence pictures. Infected cells showed TurboFP635 and GFP expression as marker for 

























Figure 21. Overlays of fluorescence and bright-field pictures from double-infected human 
tumor cell lines, VACV GLV-1h254 prior to MeV-GFP 
ACHN (A), HCT15 (B) and KM12 (C) cells were plated in 24-well plates as listed in Table 2. 
Cells were either infected by VACV GLV-1h254 at ascending MOIs from 0.001 to 0.05 (KM12), 
respectively up to 0.1 (ACHN, HCT15), or mock-treated. Secondary virus infection with MeV-
GFP at MOI 1 took place at 2, 6 or 12 hpi (row three to eight). Single virus infections as controls 
were performed with MeV-GFP (right column) at each time point (0, 2, 6, 12 hpi), respectively 
with VACV (first and second row) at 0 hrs. Pictures were taken at 4 dpi (ACHN, HCT15) prior to 
SRB assay analysis, respectively at 1 dpi (KM12). Fluorescence pictures are overlays. Infected 
cells show TurboFP635 and GFP expression as marker for viral gene expression, as well as 
plaque (VACV) and syncytia (MeV) formation. Scale bar in the right corner applies to all panels. 










Analysis by SRB assay (Figure 22) revealed that all three cell lines single-
infected by VACV GLV-1h254 at MOI 0.001 and 0.01, respectively at 0.005 
(KM12) (columns in red), and by MeV-GFP at MOI 1 (columns in green) showed 
no or only slight oncolytic effects.  
In contrast, double-treated cells presented a convincing oncolytic effect, when 
infected by VACV at MOI 0.001 or 0.01, respectively 0.005 (KM12), followed by 
MeV-GFP at MOI 1 (columns in yellow).  
In ACHN and KM12 cells differences between time points of secondary virus 
infection were negligible (neighboring columns in yellow did not reveal any 
major differences); for HCT15 cells, however, best results were achieved at 
6 hpi.  
In the single-infection treatment group, the application of higher MOIs of VACV 
led to cell mass reduction below 75 % remaining cell mass. Accordingly, we 
further on concentrated on VACV infections employing only one definite MOI; 
i.e., MOI 0.01 for tumor cell lines ACHN and HCT15, and MOI 0.005 for tumor 
cell line KM12, used for any further investigations. 
 
 






Figure 22. Cytopathic effects of combinatorial treatments with VACV GLV-1h254 prior to 
MeV-GFP in SRB viability assay. 
ACHN, HCT15 and KM12 cells were plated in 24-well plates 1 dbi (ACHN), respectively 2 dbi 
(HCT15 and KM12 cells) as listed in Table 2. Cells were either inoculated in quadruplicates with 
VACV GLV-1h254 at ascending MOIs from 0.001 to 0.05 (KM12), respectively from 0.001 to 0.1 
(ACHN, HCT15), or mock-treated. Single-infected controls at all applied MOIs were 
implemented (red columns). Secondary virus infection with MeV-GFP at MOI 1 took place at 2, 





at 0 hrs), single virus infections with MeV-GFP were performed as controls (green columns). 
Plates were incubated until 96 hpi with the first virus, the remaining cell mass was measured by 
SRB assay. Mock-treated controls were set 100 %. Dotted lines highlight the 50 and 75 % 
remaining cell mass. Values are means of three independent experiments. Error bars: SD. 
 Combinatorial treatment - MeV infection prior to infection with VACV 
In section 3.2.1, tumor cells were infected with VACV first. Here, we infected 
vice versa and inoculated initially with MeV-GFP at ascending viral 
concentrations.  
For this purpose, ACHN, HCT15 and KM12 cells were either infected by MeV-
GFP at MOI 0.001, 0.01, 0.1 and 1, or mock-treated.  
Secondly, tumor cells were either infected by VACV GLV-1h254 at MOI 0.01 
(ACHN, HCT15), respectively MOI 0.005 (KM12), at 2, 6 or 12 hpi or medium 
was added to mock-treated and single-infected wells.  
VACV single-infected controls were performed for each time point (2, 6, 12 hpi). 
Additionally, one plate was single-infected by VACV and MeV-GFP at “0 hrs” to 
generate a 0 hrs reference. Plates were incubated until 96 hpi.  
Virus-encoded fluorescent proteins were observed daily under a fluorescence 
microscope. At the end of viral treatment, plates were fixed and analyzed by 



















Figure 23. Application scheme for double-infections, MeV-GFP prior to VACV GLV-1h254  
Cells were plated in 24-well plates as listed in Table 2. On the infection day, cells were 
inoculated in quadruplicates with MeV-GFP at ascending MOIs from 0.001 to 1, or mock-
treated. Secondary virus infection with VACV at MOI 0.01 (ACHN, HCT15), respectively 0.005 
(KM12) took place at 2 (A), 6 (B) or 12 (C) hpi. At each time point, single virus infections with 
VACV were performed as controls. Plates were incubated until 96 hpi with the first virus. The 
remaining cell mass was measured by SRB assay. 
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As shown in Figure 25, infected cells were detected by vaccinia virus-encoded 
TurboFP635 and measles vaccine virus-encoded GFP expression. In bright-
field microscopy pictures, the resulting cytopathic effect was visualized by 
plaque formation (VACV) and syncytia building (MeV-GFP).  
Expectedly, at ascending viral concentrations the number of MeV-infected cells 
increased in all tumor cell lines (ACHN, HCT15 and KM12).  
For HCT15 and KM12 cells, we noticed differences in TurboFP635-expression. 
Thus, at 6 hpi, less HCT15 cells expressed the fluorescent, at 12 hpi, much 
more KM12 cells glowed red compared to cells inoculated at other time points. 
For ACHN cells, no major differences were perceived.  
Furthermore, the phenomenon of “viral competition” was observed again, now 
for the combinatorial order “MeV infection prior to infection with VACV”: 
Sequentially treated ACHN and HCT15 cells (rows three to eight of each picture 
collection, Figure 25) were found to be either infected by VACV or by MeV, but 
not by both viral vectors.  
 According to the concentration of the viral vector being applied first, tumor 
cells were either already “occupied” (when infected at high MOIs) or “free” 
for secondary virus infection with the other virus type (see also Figure 24 as 
a closeup view).  
 In KM12 tumor cells, however, this phenomenon was not observed. Quite 
the contrary, coinfected KM12 tumor cells at 6 and 12 hpi expressed 











Figure 24. Fluorescence and bright-field pictures from combinatorial infected ACHN 
cells, MeV-GFP prior to VACV GLV-1h254 at 2 hpi. Selection of Figure 25 
ACHN cells were seeded in 24-well plates and either infected by MeV-GFP at MOI 0.01 (A) or 







MOI 0.01. At 4 dpi, fluorescence (TurboFP635, GFP) and bright-field (BF) pictures were taken 
using Olympus IX50 fluorescence microscope. The image in the bottom right corner shows the 
overlay of both fluorescence pictures. Infected cells showed TurboFP635 and GFP expression 
as marker for VACV and MeV-GFP viral gene expression. Scale bar in the right lower corner 


















Figure 25. Overlays of fluorescence and bright-field pictures from double-infected human 
tumor cell lines, MeV-GFP prior to VACV GLV-1h254 
ACHN (A), HCT15 (B) and KM12 (C) cells were plated in 24-well plates as listed in Table 2. 
Cells were either infected by MeV-GFP at ascending MOIs from 0.001 to 1, or mock-treated. 
Secondary virus infection by VACV GLV-1h254 at MOI 0.01 (ACHN, HCT15), respectively 
MOI 0.005 (KM12), took place at 2, 6 or 12 hpi (row three to eight). Single virus infections as 
controls were performed with VACV (right column) at each time point (0, 2, 6, 12 hpi), 
respectively at 0 hrs with MeV-GFP (first and second row). Pictures were taken at 4 dpi prior to 
SRB assay analysis. Fluorescence pictures are overlays. Infected cells show TurboFP635 and 
GFP expression as marker for VACV and MeV-GFP viral gene expression, as well as plaque 
formation (VACV) and syncytia building (MeV-GFP). Scale bar in the right lower corner applies 
to all panels.  
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In a next step, the cytopathic effect in this experiment was examined by SRB 
viability assay (Figure 26). As a result, double-infected ACHN and KM12 tumor 
cells (columns in yellow) showed improved rates of oncolysis. Particularly, 
tumor cell masses were reduced below 75 % remaining cell mass when tumor 
cells were inoculated with MeV-GFP at MOI 1 followed by VACV GLV-1h254 at 
MOI 0.01 (ACHN), respectively MOI 0.005 (KM12). HCT15 cells, on the 
contrary, did not benefit from sequential infections. 
Except for ACHN and KM12 cells treated with MeV-GFP at the highest 
MOI (MOI 1), MeV-GFP infected controls (columns in green) showed no 
oncolytic effect. Controls of VACV infection (columns in red) revealed variations 
dependent on different time points of secondary virus treatment. Especially, 















Figure 26. Cytopathic effect of combinatorial treatment with MeV-GFP prior to VACV GLV-
1h254  
ACHN, HCT15 and KM12 cells were plated in 24-well plates as listed in Table 2. Cells were 
either inoculated with MeV-GFP at ascending MOIs from 0.001 to 1 or mock-treated. 




Single-infected controls were implemented (green columns). Secondary virus infection by VACV 
GLV-1h254 at MOI 0.01 (ACHN, HCT15), respectively MOI 0.005 (KM12) was performed at 2, 6 
or 12 hpi with the first virus (yellow columns). At each time point (2, 6, 12 hpi and additionally at 
0 hrs), single virus infections with VACV as controls were executed (red columns). Plates were 
incubated until 96 hpi with the first virus, the remaining cell mass was measured by SRB assay.  
Mock-treated controls were set 100 % (grey column 1 to 4 at 0, 2, 6 and 12 hpi). Dotted lines 
highlight the 50 and 75 % remaining cell mass. Values are means of three independent 
experiments. Error bars: SD. 
 
When taking the results detailed in section 3.2.1 into account, the following 
annotations had to be made: 
 Oncolysis was best, when VACV was applied prior to MeV.  
 Different time points of secondary virus infection (2, 6 or 12 hpi) modified 
the cytotoxic effect only marginally. Nevertheless, best results were 
ascertained at 6 hpi.  
Resulting, tumor cell lines were double-infected with MeV-GFP as secondary 
virus at 6 hpi in the following trials. 
3.3 Combinatorial treatment - VACV prior to modified MeV infection  
Next, we wanted to investigate whether an improved cytotoxic effect of the 
combinatorial treatment regime was due to synergistic or just additive effects.  
Thus, cells were infected by VACV at MOI 0.01 (ACHN, HCT15), respectively at 
MOI 0.005 (KM12) first or mock-treated.  
On the assumption that a synergistic effect would already appear at slightly 
lower MOIs of the second virus, cells were double-infected by MeV-GFP at 
ascending viral concentrations (MOI 0.1, 0.25, 0.5 and 1) at 6 hpi or medium 
was added. Virus-encoded fluorescent proteins were observed daily to monitor 
virus infection and spreading. At 96 hpi with the first virus, plates were analyzed 







Figure 27. Application scheme for double-infections, VACV GLV-1h254 prior to MeV-GFP 
at 6 hpi at ascending viral concentrations  
Cells were plated in 24-well plates and infected in quadruplicates by VACV GLV-1h254 at 
MOI 0.01 (ACHN, HCT15), respectively MOI 0.005 (KM12), or mock-treated. At 6 hpi, cells were 
double-infected by MeV-GFP at ascending viral concentrations (MOI 0.1, 0.25, 0.5 and 1) or 
medium was added to mock-treated and single-infected wells. Plates were incubated until 
96 hpi with the first virus.  
 
Infected cells showed red (VACV) and green (MeV) fluorescence, as well as 
plaque formation and syncytia building in the corresponding bright-field pictures 
(Figure 28). At ascending viral concentrations of the second virus, the number 
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Figure 28. Overlays of fluorescence and bright-field pictures from combinatorial infected 
human tumor cell lines, VACV GLV-1h254 prior to MeV-GFP at 6 hpi 
ACHN (A), HCT15 (B) and KM12 (C) cells were plated in 24-well plates as listed in Table 2. 
Cells were either infected by VACV at MOI 0.01 (ACHN, HCT15), respectively MOI 0.005 
(KM12), or mock-treated. At 6 hpi, MeV-GFP at ascending MOIs from 0.001 to 1 or medium was 
added to mock-treated and VACV single-infected cells. Pictures were taken at 3 dpi. 
Fluorescence pictures are overlays. Infected cells show TurboFP635 or GFP expression as 
marker for VACV or MeV-GFP viral gene expression, as well as plaque formation (VACV) and 
syncytia building (MeV-GFP). Scale bar in the right lower corner applies to all panels.  
  
  
Results of a subsequent SRB assay analysis (Figure 29) displayed the 
following:  
 No synergistic effect was found. The plotted cell mass reduction of double-
infected cells (columns in yellow) was commensurate to the increased MOIs 
of MeV-GFP (columns in green). 
 Worth mentioning, HCT15 cells were only slightly diminished at ascending 
viral concentrations and showed less oncolytic efficiency than in previous 


















Figure 29. Cytopathic effect of combinatorial treatment with VACV GLV-1h254 prior to 
MeV-GFP at 6 hpi in SRB assays 
ACHN, HCT15 and KM12 cells were plated in 24-well plates as listed in Table 2. Cells were 
either inoculated in quadruplicates with VACV GLV-1h254 at MOI 0.01, respectively MOI 0.005 
(KM12), or mock-treated. MeV-GFP infection followed at 6 hpi at MOI 0.1, 0.25, 0.5 or 1 (yellow 
columns), or medium was added to mock-treated and VACV single-infected (red column) cells. 
Single-infections with MeV-GFP as controls are pictured on the right side of the dash (green 
columns). Plates were incubated until 96 hpi with the first virus, the remaining cell mass was 
measured by SRB assay. Mock-treated (grey columns) controls were set 100 %. Dotted lines 
highlight the 50 and 75 % remaining cell mass. Values are means of three (KM12), four (ACHN) 
and six (HCT15) independent experiments. Error bars: SD. 
3.4 Comparison between SRB and MTT assay results 
To assure that the measured cell mass reduction, analyzed by SRB assay, 
actually represented cell death, MTT assay was complementarily performed 
and results were compared. Since plates were not only fixed and analyzed at 96 
hpi, but additionally at 0, 24, 48 and 72 hpi, it was possible to plot changes in 
cell masses over the course of the entire incubation period. As a proof of 
principle, the comparison between SRB and MTT assay results was done for 
ACHN cells only.  
Accordingly, ACHN cells were seeded in 24-well plates and infected in 





cells were inoculated with MeV-GFP at MOI 1 as second virus or DMEM was 
added to mock-treated and VACV single-infected cells. One plate was fixed 
prior to infection (0 hrs) both for the SRB and MTT method. Double-infected 
plates were incubated for 24, 48, 72 or 96 hpi, fixed with TCA and analyzed by 
SRB or MTT assay. Values were plotted in relation to “0 hrs” and in relation to 
mock. Additionally, virus-encoded TurboFP635 and GFP were monitored daily 




Figure 30. Application scheme for double-infections, VACV GLV-1h254 prior to MeV-GFP, 
24-96 hpi 
ACHN cells were plated in 24-well plates and infected in quadruplicates the next day. First, 
VACV was applied at MOI 0.01 or cells were mock-treated. At 6 hpi, infected and uninfected 
cells were inoculated with MeV-GFP at MOI 1, medium was added to mock-treated and VACV 
single-infected wells. Plates were incubated 24, 48, 72 or 96 hpi with the first virus. Cell mass 
was measured by SRB or MTT assay.  
 
As shown in Figure 31, infected cells were examined daily under a fluorescence 
microscope to supervise the process of infection and spreading in ACHN cells. 
Whereas at 1 dpi, there was almost no fluorescence detectable, at 4 dpi, 
infected cells showed high intensities of green and red fluorescence. Mock-
treated cells were uninfected and viable at 4 dpi.  
In conclusion, the combinatorial treatment with VACV 6 hrs prior to MeV-GFP 
infection was successfully conducted and equal conditions could be ensured for 
the following analysis by SRB (A) or MTT (B) assay.  









Figure 31. Overlays of fluorescence and bright-field pictures from combinatorial infected 
ACHN cells, VACV GLV-1h254 prior to MeV-GFP at 6 hpi, 1-4 dpi 
ACHN cells were plated in 24-well plates (A = SRB), (B = MTT) and either infected by VACV at 
MOI 0.01 or mock-treated. At 6 hpi, MeV-GFP at MOI 1 was added to uninfected (right column) 
and infected cells (fourth column) or medium was added to mock-treated (first and second 
column) and VACV single-infected (third column) cells. Cells were observed and pictures were 
taken daily under a fluorescence microscope. Fluorescence pictures are overlays. Infected cells 
show TurboFP635 and GFP expression as marker for VACV and MeV-GFP viral gene 






Analysis by SRB and MTT assay are depicted below (Figure 32). Expectedly, 
the highest cytotoxic effects were reached in combinatorial treated cells (A). 
Uninfected controls, measured by SRB assay, proliferated well until 72 hpi, at 
96 hpi, however, cells reached a plateau. In MTT assay, mock-treated cells 
proliferated until 96 hpi, but means showed larger standard deviations.  
In another representation of the data, when values from mock-treated cells were 
set 100 % and other values were plotted in relation to the corresponding mock, 
best cell mass reductions were obtained in double-infected cells at 96 hpi, with 
































Figure 32. Comparison between SRB and MTT assay results. Cytopathic effect of 
combinatorial treatment of ACHN cells with VACV GLV-1h254 prior to MeV-GFP at 6 hpi 
relative to 0 hrs (A), relative to mock (B) 
ACHN cells were plated in 24-well plates. The next day, one plate/trial was fixed prior to 
infection to gain output values (“0 hrs”, A), other cells were either infected by VACV at MOI 0.01 
or mock-treated. At 6 hpi, MeV-GFP MOI 1 was added to VACV-infected or uninfected cells  
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(MeV single control) or medium was added to mock-treated and VACV single-infected wells. At 
24, 48, 72 and 96 hpi with the first virus, cells were fixed and measured by SRB or MTT assay. 
Values are means of three independent experiments and were either plotted as relative to 0 hrs 
(A) or as relative to mock (B) at 24, 48, 72 and 96 hpi. B: Grey columns show mock-treated 
(uninfected) controls, which were set 100 %. Dotted lines highlight the 50 and 75 % remaining 
cell mass. Red (VACV) and green (MeV) columns represent single-infected controls, yellow 
columns show combinatorial treated cells. Error bars: SD.  
3.5 Monitoring of viral marker gene expression to further investigate the 
phenomenon of “viral competition”  
 Fluorescence microscope Olympus IX50 images 
In sections 3.2.1 and 3.2.2, fluorescence pictures showed VACV and MeV-GFP 
infected cells at 4 dpi. At this time point, the cell layer of coinfected cells was 
already diminished to a great extent. Consequently, one might assume that the 
impression of “viral competition” was only received because less viable cells 
remained (after infection with the first agent), which could be infected in the 
second round, and subsequently express the fluorescent marker protein of the 
second virus. In order to exclude this assumption, we here present another set 
of bright-field and fluorescence pictures of sequentially infected ACHN cells 
taken at 2 dpi. Cells were plated and infected as described in section 3.2.1.  
As pictured in Figure 33, the corresponding bright-field images of sequentially 
infected ACHN cells ascertained vitality at 2 dpi. Nevertheless, infected cells, 
visualized by VACV-encoded TurboFP635 and measles vaccine virus-encoded 
GFP expression, exhibited “viral competition”.  
 The majority of ACHN cells, infected first with GLV-1h254 at MOI 0.01 
and second by MeV-GFP at MOI 1, expressed GFP.  
 At a tenfold higher MOI of VACV (MOI 0.1), ACHN cells expressed 
mainly the red fluorescent protein TurboFP635, although the viral 
concentration of MeV-GFP did not change.  
Cells expressed either TurboFP635 or GFP but not both viral marker proteins at 
the same time. Thus, “viral competition” arose independent of the condition of 
the cell layer. 






Figure 33. Fluorescence and bright-field pictures from combinatorial infected ACHN 
cells, VACV GLV-1h254 prior to MeV-GFP at 2 hpi  
ACHN cells were seeded in 24-well plates and either infected by VACV at MOI 0.01 (A) or 





















































































At 2 dpi, fluorescence (TurboFP635, GFP) and bright-field (BF) pictures were taken using 
Olympus IX50 fluorescence microscope. The image in the bottom right corner shows the 
overlay of both fluorescence pictures. Infected cells showed TurboFP635 and GFP expression 
as marker for VACV and MeV-GFP viral gene expression. Scale bar in the right lower corner 
applies to all panels.  
 All-in-One BZ-9000 fluorescence microscope pictures 
In previous sequential infection trials we observed that the majority of cells 
expressed either red or green fluorescent. Nevertheless, singular cells glowed 
yellow, which might indicate coinfection of one and the same cell by VACV and 
MeV-GFP.  
To further distinguish between an actual superinfection and overlapping of 
neighboring, fluorescent-emitting cells, the Keyence microscope was applied. 
With the All-in-One BZ-9000 fluorescence microscope we were able to follow up 
viral marker gene expression in a real-time manner and, moreover, to monitor 
the infection of singular cells by ensured planar cell growth. 
For this purpose, ACHN tumor cells were plated at 1.5 x 104 cells/well in an 
open µ-Slide with 8 wells and incubated with VACV at MOI 0.01 or mock-treated 
the next day. At 6 hpi, second virus infection with MeV-GFP at MOI 1 was 
performed. Each well was reviewed for expression of viral marker proteins. 
Thus, virus-encoded GFP and TurboFP635 expression were observed 
constantly until 98 hpi using the All-in-One BZ-9000 fluorescence microscope 
(KEYENCE, Osaka, Japan).  
In Figure 34, digital images of sequentially infected cells at 63 hrs (counted from 
the beginning of the record) are presented. Here, a subconfluent cell layer 
ensured planar cell growth and therefore monitoring of singular cells.  
Using this technique, the following result was obtained:  
 Superinfections of one and the same cell arose at a quite low frequency 
(arrows point to double-infected cells). The majority of ACHN cells revealed 
sole infection either by VACV or by MeV-GFP. 
 





Figure 34. All-in-One BZ-9000 fluorescence microscope pictures of sequentially infected 
ACHN cells, VACV GLV-1h254 prior to MeV-GFP at 6 hpi 
ACHN cells were plated in an open µ-Slide and inoculated first with VACV GLV-1h254 at 
MOI 0.01, followed by MeV-GFP infection at MOI 1 at 6 hpi. At 63 hrs (counted from the 
beginning of the record), fluorescence and bright-field pictures were taken using All-in-One BZ-
9000 fluorescence microscope. The upper photo shows an overlay of the lower images and the 
corresponding bright-field picture. VACV infected cells express TurboFP635, MeV infected cells 










3.6 Western blot analysis - viral protein expression in infected ACHN cells  
Electrophoresis and western blot were implemented to investigate the 
expression of virus-specific proteins. In order to monitor changes in cell masses 
over the course of the entire incubation period and to detect its influence on 
viral protein expression, we abstained from harmonization of the protein 
content. Thus, the 8-15 % gradient gel SDS-PAGE was performed without 
protein quantification and equalization by Bradford assay. Vinculin was chosen 
as loading control. 
ACHN cells were plated at 5 x 104 cells/well in 24-well plates and incubated 
overnight. The next day, after determination of the current cell count, cells were 
infected by VACV at MOI 0.01 or mock-treated. At 6 hpi, cells were either 
additionally infected with MeV-GFP at MOI 1 or medium was added to mock-
treated and VACV single-infected wells. At 24, 48, 72 and 96 hpi, cell lysates 
were prepared for the following analysis by Western blot. 
The following results (Figure 35) were ascertained: 
 Western blot analysis approved the expression of the viral proteins ß-
galactosidase and Vaccinia (antigen A27L) for VACV (A), respectively N-
protein and GFP for MeV (B).  
 As expected, Vinculin showed alterations of the protein content over the 
course of time. Whereas mock-treated cells survived until 96 hpi, VACV 
single- and double-infected cells exhibited reduced protein contents from 
72 hpi on. Contrarily, Vinculin of MeV single-infected cells indicated high 
remnant cell mass at 72 hpi. 
 VACV single- and double-infected cells exhibited increased expression of ß-
galactosidase and Vaccinia antigen A27L at 72 hpi. At 96 hpi, however, the 
expression of both viral proteins decreased (A). Furthermore, we monitored 
a slight difference between the VACV single and double infection group. At 
72 and 96 hpi, the expression of Vaccinia antigen A27L in single-infected 
cells was higher than in double-infected cells. The expression of ß-
galactosidase, however, showed no alterations.  




 Similarly, Western blot analysis showed enhanced expression of MeV viral 
proteins (N-protein and GFP) in single- compared to double-infected cells at 







Figure 35. Western blot analysis of viral protein expression in ACHN cells 
ACHN cells were plated at 5 x 104 cells/well in 24-well plates. The next day, cells were either 
infected with VACV at MOI 0.01 or mock-treated. At 6 hpi, cells were inoculated with MeV-GFP 
at MOI 1 or medium was added to single-infected and mock-treated cells. Cells were harvested 
24, 48, 72 and 96 hpi. Lysates of mock-treated, single- and double-infected cells were 
separated by 8-15 % gradient SDS-PAGE and blotted on a PVDF membrane. Antibodies 
against Vinculin were used for “housekeeping” protein detection as loading control (A, B).  
Viral protein detection was realized by using antibodies against ß-galactosidase and Vaccinia 
antigen A27L (VACV) (A), and antibodies against MeV N-protein and GFP (MeV-GFP) (B). 
VACV was detected at 14 kDa, GFP at 27 kDa, MeV N-Protein at 58 kDa, Vinculin at 115 kDa 








Although the combined application of standard care and novel therapeutics has 
recorded considerable successes in the treatment of various cancers, a 
complete, sustainable remission remains rare.  
Oncolytic viruses can be designed to complement established treatment 
modalities, thus, offering a promising attempt to handle metastatic disease. 
These anticancer agents fight tumors both by direct cell killing and the here-
inafter establishment of a specific antitumor immune response (Kaufman et al, 
2015). Naturally or by genetic engineering, virus constructs are exclusively 
directed against cancerous cells, while normal tissue is spared (Russell & Peng, 
2007; Russell et al, 2012). 
Remaining obstacles to a successful application of virotherapy have been over-
come in some cases, as indicated by the accreditation of adenovirus H101 in 
2005 (Garber, 2006; Jiang et al, 2006) and herpes simples virus T-VEC in 2015 
(Andtbacka et al, 2015; Ledford, 2015; Zhang, 2015).  
Nevertheless, inherent resistance of cancer cells towards oncolytic virus 
treatment remains a major issue. Thus, maintained antiviral activity of cancer 
cells hinders oncolytic viruses to completely eradicate tumor sides (Russell et 
al, 2012).  
Besides other approaches, Le Boeuf et al. applied the attenuated Western 
Reserve strain of vaccinia virus together with a vesicular stomatitis virus to 
circumvent cellular innate immunity of highly resistant tumor cells (Le Boeuf et 
al, 2010). Furthermore, Tysome et al. performed sequential infections using the 
attenuated Lister vaccine strain of vaccinia virus and wildtype adenovirus 
(Tysome et al, 2012). Both research teams were able to demonstrate that a 
combinatorial treatment regime was superior to single virus infections.  
The susceptibility to cellular innate antiviral immune response is traded as a 
central issue to a successful application of oncolytic viruses. Le Boeuf et al. 
revealed that some high resistant tumor cell lines derived from the NCI-60 panel 
are equipped with partial responsiveness to IFN (Le Boeuf et al, 2010).  




Subsequently, the researchers applied a double-deleted vaccinia virus to com-
plement a recombinant VSV version, which replication and spreading is most 
effectively hindered by IFN (Le Boeuf et al, 2010). The authors confirmed that a 
combined application of both virus constructs did not only support infection and 
spreading of VSV; moreover, it established the basis for synergistic interaction 
(Le Boeuf et al, 2010).  
Here, in this wok, we set out to investigate whether these findings are 
reproducible when now applying the virotherapeutic vector GLV-1h254 (being 
derived from the attenuated Lister strain of vaccinia virus) together with 
oncolytic measles vaccine virus MeV-GFP.  
The application of immunological distinct viruses may not only increase chances 
for multiple virus infections, but improve tumor cell destruction by collaboration 
of both viral agents in multiple ways (Le Boeuf et al, 2010; Tysome et al, 2012).  
Three out of five tumor cell lines investigated in this thesis, i.e., ACHN, HCT15 
and KM12, have been defined resistant to VACV infection by Ascierto et al. 
(Ascierto et al, 2011). The treated cell lines exhibited a most heterogeneous 
susceptibility to GLV-1h68, a close relative to GLV-1h254. Thus, resistance was 
not only found to be independent of tumor cell origin, it was also found to be 
independent of the chosen vaccinia virus strain in further investigations 
(Ascierto et al, 2011). When results were confirmed by the application of a VSV, 
Ascierto et al. were convinced that common virotherapy resistance patterns 
must exist (Ascierto et al, 2011). Additionally, ACHN, HCT15 and KM12 cells 
were declared highly resistant to MeV-SCD infection (Noll et al, 2013). Noll et 
al. suspected the incomplete blockage of the innate cellular immune defense of 
these tumor cell lines as crux of the matter (Noll et al, 2013). Thus, a functional 
IFN release upon MeV-SCD infection is traded as key mechanism to a reduced 
susceptibility to virus infection (Noll et al, 2013).  
Recombinant vaccinia virus GLV-1h68 has been assigned for the treatment of 
human sarcomas as well (He et al, 2012). He et al. detected oncolytic activity 
against fibrosarcoma, osteosarcoma, fibrohistiocytoma and rhabdomyosarcoma 





cells appeared quite high (MOI 5) and supports the presumption that 
responsiveness to oncolytic virotherapy was weaker than intended. Although 
SRH and CCS cells, two sarcoma cell lines investigated in this thesis, were not 
evaluated by this research group, cell lines were found to be resistant to MeV-
SCD infection by Berchtold et al. (Berchtold et al, 2013). Although CD46 
expression and primary infection were guaranteed for both cell lines, SRH and 
CCS cells presented either a transient or “slow and weak” virus production in 
viral growth curve analysis (Berchtold et al, 2013). Berchtold et al. attributed 
these findings to differential patterns of innate immune defense. Thus, MeV-
SCD infection resulted in a strong induction of RIG-I and IFIT1 in SRH cells 
(Berchtold et al, 2013). 
4.1 Tumor cell resistance against oncolytic virotherapy is relative and can 
be diminished by ascending viral concentrations.  
First, it was necessary to define threshold MOIs for each viral vector in single 
infection approaches to satisfy the criterion of resistance, defined as cell mass 
reduction of less than 25 % compared to uninfected controls 96 hpi. As 
demonstrated repeatedly by applying VACV and MeV at ascending viral 
concentrations, tumor cell resistance is relative and can be partially overcome 
by increased virus titers. Evidence of this observation has also been provided 
by other members of our group (Berchtold et al, 2013; Lange et al, 2013; Noll et 
al, 2013; Yurttas et al, 2014).  
Now, one might assume that the hurdle of resistance could be overtaken by 
simply employing elevated virus titers; however, this approach cannot be traded 
as a serious solution. At first, the production of high titer lysates has already 
become a challenge since most viruses are propagated in laborious tissue 
cultures (Kaufman et al, 2015). Secondly, even if a high titer production is 
feasible, premature viral clearance, neutralization of virus particles and limited 
virus delivery may represent further obstacles in vivo.  
Moreover, as demonstrated in this thesis, resistant tumor cell lines are not 
completely erased, but “only” diminished at ascending viral concentrations. As a 




consequence, surviving tumor cells, for example non-cycling cells, may prepare 
the breeding ground for new tumor growth soon afterwards (Kaufman et al, 
2015). Resulting, we here established a treatment regime applying two different 
virus constructs in order to fight cancer by interlocking mechanisms.  
4.2 Determination of threshold MOIs depends on cellular confluence.  
As suggested by previous work from C. Raff (unpublished data) and M. Noll 
(Noll et al, 2013), who had screened the commonly applied NCI-60 panel for its 
susceptibility either to VACV- or MeV-based virotherapeutics, we initially plated 
all tumor cell lines equally (section 3.1.1). For reasons of practicability, we 
additionally seeded the sarcoma cell lines SRH and CCS uniformly. Whereas 
ACHN and HCT15 cells grew well and were considered to be ready to VACV-
infection already the next day, KM12, CCS and SRH cells revealed insufficient 
confluence 1 dpi.  
The following analysis by SRB viability assay provided corresponding results: 
While values of ACHN and HCT15 cells showed small standard deviations, 
those of KM12, SRH and CCS differed enormously. Moreover, even though the 
experimental setting was comparable, our SRB assay results diverged from the 
results previously obtained by C. Raff. Based on this finding, we decided to 
have a closer look at the chosen initial cell counts, resulting confluence and 
growth inhibition, and its influence on virus spreading. 
Thus, so called “confluence trials” were performed to optimize the density of cell 
layers right before virus infection, as well as to guarantee survival of mock-
infected controls until the end of the experiment. We noticed that (i) pro-
longation of the time that HCT15, KM12, SRH and CCS cells were plated before 
any subsequent infection, as well as (ii) increased initial cell counts (CCS and 
KM12) led to enhanced cell density and therefore confluence.  
Encouraged by Niepel et al., who recommended to take diverging cell division 
times into account, we then determined individual incubation periods and plating 





However, we have to admit that the survival of mock-infected cells was not 
guaranteed by these "confluence trials”. Since monitoring of cell density was 
performed with the naked eye, analysis was most vulnerable to error. A clear 
differentiation between a confluent and an overgrown well was not practicable, 
especially with cell lines such as CCS and KM12 that agglomerated quickly 
(independent of their initial cell count) but never reached total confluence.  
In accordance, Skehan et al. have reported problems concerning fixation of 
cells growing as floating aggregates (Skehan et al, 1990). Moreover, Niepel et 
al. emphasized the underestimated relevance of interfering factors to drug 
sensitivity assays like SRB (Niepel et al, 2017). The authors underlined that the 
condition of the applied cell culture at the time point of seeding, initial cell 
counts and cell division time “are (...) variables with a substantial impact on cell 
proliferation” (Niepel et al, 2017). Since evidence grows that high cell numbers 
support drug resistance (Chauffert et al, 1998; Dimanche-Boitrel et al, 1993; 
Fang et al, 2007; Garrido et al, 1995; Hafner et al, 2016; Niepel et al, 2017), 
Niepel et al. suggest to perform experimental trials in the time frame of steady 
state growth (Niepel et al, 2017). 
VACV infected “optimized-plated” SRH and CCS cells (section 3.1.3) showed 
reduced cell masses, when compared to non-optimized plated cells (section 
3.1.1). Improved virus spreading due to tighter cell-to-cell contacts may offer an 
explanation. Worth mentioning, washing steps of the applied SRB assay were 
accidentally modified: after staining with SRB dye, plates were washed once 
with tap water instead of using 1 % acetic acid for washing exclusively. As this 
aminoxanthene dye dissociates under basic conditions, the remained cell mass 
may have been underestimated (Skehan et al, 1990; Vichai & Kirtikara, 2006). 
On the contrary, since this mistake affected all treated cell lines and not only 
SRH and CCS cells, the interference might be negligible. Surprisingly, although 
fluorescence pictures of infected HCT15 and KM12 cells (section 3.1.3) showed 
large plaque forming units (HCT15) and a high proportion of TurboFP635 
expression at higher MOIs, cell masses were even less reduced than before 
(see section 3.1.1). We presume that suitable initial cell counts might have led 
to a more sufficient cell attachment and reduced cell loss during procedure 




steps of the SRB assay (Vichai & Kirtikara, 2006). Additionally, lower standard 
deviations of KM12 cells supported this conclusion.  
In MeV single infection trial (section 3.1.4), virus infection was successfully 
conducted, demonstrated by virus-encoded GFP expression and syncytia 
formation in all cell lines, except for SRH. Although analysis of SRB data 
represented reduced cell masses at MOI 1 and 10, SRH cells seemed only 
marginally infected on the belonging overlay pictures. A closer examination of 
these photographs exhibited a subconfluent cell layer of SRH cells at 96 hpi. 
Poor cell-to-cell contract might have led to reduced virus spreading, and, 
consequently, limited virus marker gene expression. In accordance, Berchtold 
et al. declared SRH and CCS cells as resistant to MeV-SCD infection (Berchtold 
et al, 2013). For HCT15 cells, overlays of fluorescence and bright-field pictures 
revealed marginal signs of infection, and remnants were inappreciably reduced 
at 96 hpi in SRB assay analysis. Consistent with our findings, Noll et al. defined 
ACHN, HCT15 and KM12 cells highly resistant to MeV-SCD infection at MOI 1 
(Noll et al, 2013). Whereas, ACHN and KM12 cells exhibited a primary infection 
rate > 20 % by MeV-GFP at MOI 1, less than 3 % of HCT15 cells expressed 
GFP (Noll et al, 2013). Moreover, viral growth curves exhibited only transient 
viral replication in HCT15 cells, and western blot analysis confirmed decreased 
expression of MeV-encoded proteins at 72 and 96 hpi (Noll et al, 2013). The 
researchers argued that a strong interferon response by intense expression of 
IFIT1 might be responsible for the mentioned differences between HCT15 and 
other highly resistant cell lines (Noll et al, 2013).  
To confirm findings regarding confluence, its impact on virus spreading and 
survival of uninfected controls, an xCELLigence trial was performed. By 
registration of differences in electrical impedance, cell viability and proliferation 
is evaluated in real-time (Ke et al, 2011). Contingent upon selected cell 
numbers, mock-treated ACHN cells either proliferated until 96 hpi 
(1000 cells/well, respectively 2000 cells/well), hit a plateau (4000 cells/well) or 
levelled off (8000 cells/well). This finding indicated that high plating densities 
cause growth inhibition or cell death of uninfected controls. Furthermore, the 





infected cells increased dependent on higher plating densities. Accordingly, we 
assumed that the efficiency of virus spreading and oncolysis correlates with the 
initial cell counts of infected cells and therefore with confluence. The higher the 
cell-seeding density, the better the virus spreading - as long as cells range in 
the exponential increase phase. Niepel et al. considered the xCELLigence 
platform as a reliable tool to assess confluence in real-time, nevertheless they 
emphasized its limitations, since its application is restricted to monolayers 
(Niepel et al, 2017).  
Both observations of the xCELLigence trial were affirmed by another single-
infection approach using VACV (section 3.1.5). To survey the survival of mock-
treated and infected cells reliant on initial cell counts, cells were assessed daily 
by fluorescence microscopy and SRB assay. For KM12 cells, which were plated 
at several densities, agglomeration of cells was registered independent on the 
initial cell count, but at 2 x 105 cells/well, KM12 cells overgrew and levelled off 
when analyzed by SRB assay. Accordingly, we admit that KM12 cells were 
plated far too high in previous trials. Although bright-field pictures revealed 
dense cell layers of ACHN and HCT15 cells already 1dpi, we maintained initial 
cell counts because the SRB assay result ensured proliferation until 96 hpi. 
Retrospectively, uninfected controls of ACHN and HCT15 cells indicated cell 
growth after log phase at this time point. As a consequence, plating numbers 
should have been determined by daily performance of the SRB method in the 
first place.  
In accordance with findings of the xCELLigence trial, KM12 cells were erased 
more efficiently when plated at the higher cell-seeding density. Although values 
of 2 x 105 cells/well must be interpreted with caution (since the corresponding 
mock declined at 96 hpi), cell remnants of the MOI 0.01 treatment group were 
diminished to a greater extent. Thus, we demonstrated once again that virus 
spreading is reliant of confluence. Surprisingly, at 1 x 105 cells/well, infected cell 
remnants were less reduced than at 5 x 104 cells/well. Improved cell attachment 
of 1 x 105 cells/well might have had influence.  




Finally, when results of section 3.1.5 were compared to those generated in 
section 3.1.1 and 3.1.3, respectively, we noticed differences regarding cell 
indices of remnants. In section 3.1.5, infected ACHN and HCT15 cells were 
reduced to a greater extent, although plating conditions and initial cell counts 
did not change. However, from section 3.1.5 on, we variegated the mode of 
infection: at 1.5 hpi, the virus-containing inoculum was no longer removed, but 
22 % FBS-supplemented DMEM was added to the wells. Thus, the incubation 
period of vaccinia virus particles was greatly prolonged and SRB assay results 
may display enhanced oncolysis. 
4.3 Combinatorial virus infections are superior to single infections. 
As detailed above, the extensive determination of reliable threshold MOIs for 
each viral vector was necessary in the run. Thereafter, oncolytic vaccinia and 
measles vaccine virus were examined in several application schemes in double-
infection approaches with ACHN, HCT15 and KM12 cells. Thus, different orders 
of viruses and time points of secondary virus infection were tested to identify the 
most promising design.  
In section 3.2.1, ACHN, HCT15 and KM12 cells were infected with VACV at 
various MOIs prior to MeV at MOI 1 at 2, 6 or 12 hpi. As reflected by 
fluorescence pictures, VACV marker protein expression was dependent on 
ascending viral concentrations. Moreover, we observed a phenomenon called 
“viral competition”, which is discussed in detail in section 4.6.  
As analyzed by the SRB assay, remnant cell masses of all three cell lines were 
found to be reduced more effectively when double-infected. At threshold MOIs, 
cell indices of combinatorial treated ACHN and KM12 cells were reduced below 
the critical value of 75 % remaining cell mass, independent of the time point of 
secondary virus infection. Double-treated HCT15 cells, however, reached the 
borderline only when infected with MeV at 6 hpi.  
In section 3.2.2, cells were infected vice versa (ACHN, HCT15 and KM12 cells 
were infected with MeV at various MOIs prior to “fixed-dosage (MOI)” infection 





documented in all cell lines by fluorescence pictures. In the SRB assay 
analysis, double-infected ACHN and KM12 cells showed an improved oncolytic 
effect in the 2 hpi- (ACHN), respectively 6 hpi- and 12 hpi-treatment group 
(KM12). Of note, remnant HCT15 cells did not benefit from sequential 
infections. Consequently, all three highly resistant tumor cell lines were 
combatted best when inoculated first with VACV. Moreover, at threshold MOIs 
cell indices of double-infected cells did no longer comply with the criterion of 
high-grade resistance.  
Time points for secondary virus infection were aligned to vaccinia virus life 
cycle. Since early viral mRNAs are known to suppress the emerging cellular 
immune response (Moore & Smith, 1992; Schramm & Locker, 2005; Thorne et 
al, 2005), 2 hpi appeared to be an appropriate time period for the following 
measles virus infection. Whereas differences between MeV-second-infected 
remnants at 2, 6 and 12 hpi (section 3.2.1) were found to be negligible and with-
out correlation to the belonging controls, variations in VACV-second-treated 
cells (section 3.2.2) corresponded to up- and downturns of the single-infected 
controls. Fittingly, the belonging fluorescence pictures highlighted unequal 
TurboFP635 expression in HCT15 and KM12 cells. Thus, we reasoned, 
fluctuations were most likely explainable by execution errors than by real 
differences. Nevertheless, for reasons of feasibility, we decided to further on 
perform all double-infections at 6 hpi with VACV. 
Le Boeuf et al. established a double-deleted vaccinia virus (VVDD) prior to 
recombinant VSVΔ51 to sensitize a resistant monolayer to VSV-derived onco-
lysis (Le Boeuf et al, 2010). This combination was most successful because of 
its rational design. Since Le Boeuf et al. handled partial responsiveness to IFN 
as prime suspect of a reduced susceptibility to oncolytic virotherapy, they 
applied a VACV version with a soluble IFN-receptor to suppress remaining 
antiviral immune response (Le Boeuf et al, 2010). Furthermore, even a 
synergistic effect was established by applying a VSV version that additionally 
expressed a protein, which improved the spreading of VACV.  




Here, in this work, we were challenged by the fact that ACHN, HCT15 and 
KM12 tumor cells were resistant both to oncolytic vaccinia and measles virus 
treatment. Nevertheless, since double-infections with VACV prior to MeV-GFP 
(“VACV first, MeV second”, section 3.2.1) proved to be superior both to single- 
and the “alternative round” double-infection regime (“MeV first, VACV second”, 
section 3.2.2), we reasoned that a vaccinia-mediated IFN blockage might have 
turned the scales.  
B18R, the soluble type I IFN-receptor Le Boeuf reported on, is expressed 
ubiquitously as ascertained by comparison of genome sequences of various 
vaccinia virus strains (Qin et al, 2015). Among others, Lister strain VACV107 
encodes B18R, respectively open reading frame number 194 (Qin et al, 2015). 
Accordingly, we assumed that VACV GLV-1h254 might encode this soluble IFN 
receptor as well.  
Moreover, Smith et al. reviewed that poxviruses apply a multitude of strategies 
to inhibit host antiviral responses (Smith et al, 2013). In addition to B18R, VACV 
establishes lots of immune-modulatory proteins to block complement factors, 
cyto- and chemokine production, and counteracts host cell signaling pathways 
to inhibit apoptosis and viral clearance (Smith et al, 2013).  
In another study, Tysome et al. proved that three Syrian hamster tumor cell 
lines supported viral gene expression after oncolytic adenovirus and vaccinia 
virus treatment (Tysome et al, 2012). In vitro, HPD-1NR, HPD-2NR and HaK 
cells were either infected with Ad5 or VVLister but not combined. In vivo, the 
combined application of Ad5 and VVLister erased established tumors in an 
immunocompetent Syrian hamster model. Although the study design was not 
directly comparable to our setting, the advantage of a sequential treatment 
regime was demonstrated convincingly. 
4.4 No hint of synergism - the superiority of sequential infections is 
explained by additive effects.  
In general, the combined application of drugs - in our case of two genetically 





virus) - leads to three different types of interaction. Besides the most wanted 
synergism, both addition and antagonism are alternative mechanisms. While 
synergistic interaction improves outcomes, addition fulfills and antagonism falls 
behind the expectation gained from the singular activity of each component 
(Bukowska et al, 2015).  
In this context, Le Boeuf et al. were able to induce synergism between VSV and 
VACV, both in vitro and in vivo (Le Boeuf et al, 2010). Beyond that, also 
Tysome et al. demonstrated synergistic interaction in vivo since they were able 
to halve the applied doses of Ad5 and VVLister in the combinatorial setting 
(Tysome et al, 2012). In contrast to Le Boeuf et al., who constructed their OVs 
most carefully, we hypothesized that our “unmodified” virotherapeutic agents 
might complement each other naturally. In this line, we were convinced that 
VACV-encoded immune-modulatory proteins support the infection and 
spreading of a second virus that is most dependent on IFN signaling. Moreover, 
we assumed that syncytia formation emerging upon MeV-GFP infection, would 
lead to a ping-pong effect in terms of virus infection and spreading of both 
counterparts. 
To further investigate whether there are synergistic or only additive effects, 
ACHN, HCT15 and KM12 cells were infected with VACV at defined threshold 
MOIs followed by an infection with MeV at slightly deviating viral concentrations 
6 hpi. Fluorescence pictures of HCT15 cells showed barely signs of MeV 
infection. Fittingly, cell indices of infected HCT15 cells were reduced 
inappreciably. As expected, in double-infected ACHN and KM12 cells, GFP 
expression and syncytia formation were dependent on the virus concentration 
applied, and corresponding cell masses were reduced in accordance. What is 
more, cell mass reduction of each double-infected cohort was reflected by its 
belonging single-infection treatment group. Thus, we did not receive any hints of 
synergism, but of additive effects here.  




4.5 Both viabilitiy assays, SRB and MTT, exhibit comparable results.  
SRB and MTT viability assays are widely applied colorimetric assays to 
determine cell counts after a wide variety of cytotoxic treatments. Both methods 
convince with cost-efficiency, time saving and practicability.  
Because the SRB dye binds to cellular proteins, the amount of subsequent 
dissolved dye is directly proportional to the cell number stained (Skehan et al, 
1990). Although this assay detects cytotoxic effects most accurately, it is not 
able to differentiate between viable and dead cells (Vichai & Kirtikara, 2006).  
The MTT assay, however, detects metabolic active, viable cells by enzymatic 
conversion of a tetrazolium salt into a dark-colored formazan dye (Mosmann, 
1983). Thus, the MTT assay is a great tool to review results obtained with the 
SRB method. 
In order to evaluate whether the results of the SRB assay were comparable to 
those of the MTT assay, and, moreover, to investigate, if reduction of cell mass 
actually indicated cell death, a comparative trail was performed (section 3.4).  
For this purpose, sequential infection with VACV followed by MeV was 
performed. Then, infected and uninfected ACHN cells were analyzed at 0, 24, 
48, 72 and 96 hpi with the SRB or MTT assay, respectively. Fluorescence and 
bright-field pictures ensured equal cell-seeding and comparable rates of 
infection. 
When values from mock-treated cells were set 100 % and other values were 
plotted in relation to the corresponding mock, there were no differences 
between SRB and MTT assay results detectable. Thus, we reasoned, cell mass 
reductions analyzed by SRB assay actually indicated cell death.  
Analogically, other groups have demonstrated that results of both assays are 
highly comparable (Haselsberger et al, 1996; Perez et al, 1993; Rubinstein et 
al, 1990). However, the generated signal of the MTT assay is dependent on the 
overall cell count, but in addition, it is reliant on the metabolic activity of each 
and every cell (Riss et al, 2004). Riss et al. explicated that different factors, e.g. 





produced formazan, which deregulates the “linearity between absorbance and 
cell number” (Riss et al, 2004). Consequently, the SRB and MTT method need 
to be performed at logarithmic cell phase growth (van Meerloo et al, 2011; 
Vichai & Kirtikara, 2006). In our experiment, cell growth of uninfected controls 
plateaued in the SRB assay analysis at 96 hpi. Although mock-treated cells 
proliferated until the end of the trial in the MTT assay, growth curves indicated 
that cells were measured after log phase. 
4.6 The majority of sequentially infected cells exhibits sole infection by 
“only” one virus.  
Many viruses have evolved mechanisms to prevent superinfection of an already 
“occupied”, i.e. primarily infected cell.  
For this phenomenon, downregulation of viral entry receptors, blockage of 
secondary virus RNA translation and genome replication, as well as activation 
of IFN signaling pathway are held responsible (Schaller et al, 2007).  
Prohibition of superinfection has been demonstrated for a wide variety of 
distinct viruses, such as hepatitis C virus (HCV) (Schaller et al, 2007; Tscherne 
et al, 2007), human immunodeficiency virus type 1 (Wildum et al, 2006), Old 
and New World arenaviruses (Huang et al, 2012; Huang et al, 2015), NDV (Li et 
al, 2012), rubella virus (Claus et al, 2007) and West Nile virus (Zou et al, 2009).  
Among other poxviruses, VACV is known to circumvent superinfection both by 
blockage of the “membrane fusion step” (Laliberte & Moss, 2014) and 
expression of virally encoded proteins like haemagglutinin (A56) and K2 (Turner 
& Moyer, 2008; Wagenaar & Moss, 2009), A33 and A36 (Doceul et al, 2010).  
In the majority of cases reviewed, superinfection exclusion was observed upon 
secondary virus infection with progeny of the same virus construct. In addition, 
researchers also reported of “heterologous superinfection exclusion” upon 
secondary virus infection with related or even distinct viruses (Eaton, 1979; 
Huang et al, 2015; Karpf et al, 1997; Nasar et al, 2015; Parkman et al, 1964; 
Tscherne et al, 2007).  




As illustrated by fluorescence pictures, Le Boeuf et al. observed that DsRed and 
GFP expression did mainly not occur in the same cell after coinfection with 
VACV and VSV (Le Boeuf et al, 2010). However, the oncolytic potential of this 
combinatorial approach was undoubted. Consequently, the researchers 
presumed that a “sensitization of neighboring cells” upon VACV infection must 
have led to enhanced susceptibility to the following application of VSV (Le 
Boeuf et al, 2010).  
Here, in our work, we noticed that the majority of sequentially infected cells 
were either infected by VACV or by MeV but not by both viral agents 
simultaneously (sections 3.2.1, 3.2.2 and 3.5.1). Furthermore, successful 
secondary virus infections, here monitored by viral marker gene expression, 
were demonstrated to be dependent on viral concentrations of the first agent: (i) 
at low MOIs of the first virus, cells were infected to a greater extent by the 
second virus; (ii) at higher MOIs of the first virus, it was the other way round and 
cells were already occupied by the first agent. We called this phenomenon “viral 
competition” and considered a kind of superinfection exclusion as responsible 
reason.  
By performing our Keyence trial (section 3.5.2), i.e., applying real-time All-in-
One BZ-9000 fluorescence microscope, it was possible to monitor planar cell 
growth and, more important, real-time infection of singular cells. Although the 
majority of sequentially infected cells illuminated either red or green, some cells 
were double-infected by VACV and GFP, visualized by a yellow glow. To our 
knowledge, this is the first report of “viral competition” concerning heterologous 
superinfection exclusion in regards to VACV and MeV. 
However, since analysis of SRB assays (sections 3.2.1 and 3.2.2) revealed that 
remnant cells were reduced more effectively when being infected sequentially, 






4.7 Western blot analysis verifies the observed phenomenon of “viral 
competition”: Viral protein expression is altered in double-infected cells.  
Western blot analysis was performed to confirm the expression of viral proteins 
upon combinatorial treatment with VACV and MeV, as well as to further 
investigate the observed phenomenon of “viral competition”. 
In order to study changes of cell mass over the course of the entire incubation 
period, we abstained from equalization of the protein content by Bradford assay.  
As demonstrated in section 3.6, both single- and double-infected ACHN cells 
expressed VACV and MeV proteins. From 24 to 96 hpi, alterations of the protein 
content of infected cells suggested proceeding cell loss due to virus infection 
and following oncolysis. Especially VACV-infected cells exhibited reduced cell 
masses at advanced time points. Thus, a prior finding of the SRB assay was 
confirmed: cell death of double-infected cells is most contingent upon VACV 
infection.  
In accordance to our findings, Le Boeuf et al. indicated that tumor cell infection 
by both candidates was mainly triggered by VACV (Le Boeuf et al, 2010). At 
96 hpi, ß-galactosidase and Vaccinia protein expression decreased relative to 
levels reached at 72 hpi. Since viral proteins were extracted from cell lysates, 
this observation was no surprise: at 72 and even more at 96 hpi, cell masses 
were erased almost completely; consequently, the breeding ground for 
production of new virions was diminished. Nevertheless, N-protein and GFP 
were highly expressed until 96 hpi. Thus, ACHN cells survived MeV sole 
infection until the end of the experiment. In accordance with this finding, 
N. Mayer demonstrated survival of MeV single-infected sarcoma cells until 
144 hpi (Mayer, 2014). 
Concerning the phenomenon of “viral competition”, we observed that viral 
proteins were expressed higher in single- than in double-infected cells at 72 and 
96 hpi. At these advanced time points, cells were almost completely infected by 
both viral agents, which might have triggered “viral competition” regarding 
uninfected cells. We suppose that the described phenomenon of heterologous 




superinfection exclusion contributed to this finding. Although other groups 
barely applied western blot analysis to follow up superinfection exclusion, 
Tscherne et al. indicated reduced protein levels upon secondary virus infection 







VACV- and MeV-based virotherapeutics have already proved to be safe and 
effective weapons in the fight against various cancer entities. In this thesis we 
investigated whether a combined application of VACV GLV-1h254 and MeV-
GFP in vitro would overcome limiting barriers to a successful treatment of highly 
resistant human tumor cell lines.  
In the course of the work we encountered methodical difficulties referring to cell 
viability assays. With respect to our elaborated findings, we recommend to 
determine suitable initial cell counts for each in vitro experiment by SRB assay. 
This suggestion was also made by Vichai and Kirtikara, who explain the 
procedure in detail (Vichai & Kirtikara, 2006). Thus, logarithmic cell growth of 
controls will be guaranteed until the end of the experiment, while monolayers 
are allowed to grow subconfluent. Although Skehan et al. reported about 
possible modifications of the SRB assay to fix cell aggregates, we suggest to 
apply this method only to firmly adhered cells (Skehan et al, 1990).  
Furthermore, we emphasize the importance of comparative trials. Thus, results 
are confirmed and, moreover, become accessible for further interpretation, 
demonstrated in this thesis by comparison of the SRB and MTT data. In 1992, 
Sasaki et al. introduced another cytotoxicity assay that measures the activity of 
a cytosolic enzyme, the lactate dehydrogenase (LDH), which is released upon 
cell death (Sasaki et al, 1992). While the SRB and MTT assay mirror the 
reduction of cell mass and metabolic activity, respectively, the LDH method 
actually indicates cytolysis. Accordingly, we propose to supplement the LDH 
assay in further studies.  
Another exciting side show of this thesis is the described phenomenon of “viral 
competition”. As explicated before, the majority of sequentially infected cells 
exhibited sole infection, nevertheless, singular cells were coinfected by both 
virus constructs. In 1964, Parkman et al. indicated that rubella virus interfered 
with heterologous virus constructs like enteroviruses, mumps, influenza, para-
influenza and rubeola (Parkman et al, 1964). Nevertheless, research primarily 
focuses on homologous superinfection exclusion. Further studies should pursue 




the here described phenomenon and its underlying mechanism applying 
additional methods as well as other oncolytic virus platforms.  
Moreover, the survival of MeV single-infected ACHN cells until 96 hpi (section 
3.6) attracted our interest. In a previous paragraph, we argued that the 
experimental settings of cytotoxicity assays must be kept consistent to obtain 
reliable results. Consequently, we do not advise to simply stretch time frames of 
such assays, but apply another method to detect potential delayed oncolytic 
effects. 
Primary resistance phenomenon of human tumor cell lines towards oncolytic 
virotherapy remains a major hurdle to a successful application of this novel 
approach. In this thesis, we ascertained that sequential infections with VACV 
GLV-1h254 and MeV-GFP were superior to single infections. Best results were 
achieved, when VACV was applied first, while differences between time points 
of secondary virus infection were negligible. Admittedly, we did not receive any 
hint of synergistic interaction between the applied oncolytic viruses, and additive 
effects were only marginal. Nevertheless, it might be of some interest to further 
explore the molecular mechanisms of the described viral interactions and their 
impact on IFN signaling.  
In addition, studies should investigate the potential capacity of other “oncolytic 
tag-teams” by sequential infection of a wide range of tumor entities (Le Boeuf & 
Bell, 2010). To increase the occurrence of synergistic interaction, team partners 
must be matched thoroughly. Careful evaluation of each other´s benefits and 
malfunctions will be indispensable in order to develop well-fitting counterparts. 
Regarding the complex interactions between the host immune response and 
oncolytic viruses, Tysome et al. highlighted the importance to apply 







Oncolytic viruses such as VACV and MeV are live, self-replicating biological 
anticancer agents, which have supplemented established therapies for quite a 
while (Bell, 2007). While sparing normal tissue, OVs destroy cancer cells by 
direct tumor cell lysis and the establishment of a host antitumor immune 
response (Kaufman et al, 2015). Nevertheless, primary resistance phenomenon 
to this novel approach hinders its widespread application.  
In 2010, Le Boeuf et al. published a promising attempt by demonstrating 
synergistic interaction between a VACV and a VSV strain (Le Boeuf et al, 
2010). MeV and VACV proved to be safe, and moreover, convinced in some 
cases with outstanding oncolytic efficacy. On the basis of highly resistant tumor 
cells, we here investigated in vitro whether Le Boeuf´s findings were 
reproducible for VACV GLV-1h254 and vaccine-based measles construct MeV-
GFP. In accordance with the researchers, we supposed that partial responsive-
ness to IFN could have led to a reduced susceptibility of resistant tumor cells to 
oncolytic virotherapy (Le Boeuf et al, 2010). With GLV-1h254, however, we 
aimed to suppress the upcoming host antivirus immune reaction.  
Prior to double infection trials, it was necessary to determined suitable virus 
concentrations of both vectors for each cell line. We noticed that every cell line 
required different plating densities to reach confluence and, moreover, that cell 
density influenced survival of uninfected controls as well as virus spreading. 
After determination of threshold MOIs, we examined different orders of virus 
treatment and time points for secondary virus infection in double infection trials. 
SRB assay analysis ensured the superiority of the combinatorial treatment 
regime. Thus, sequential infections applying VACV prior to MeV-GFP achieved 
best results, while differences between time points of secondary virus infection 
had only minor impact. Admittedly, synergistic interaction was not observed and 
additive effects were limited.  
Naturally, our in vitro setting is unable to reflect the complex interactions 
between oncolytic agents and the host immune response. Thus, we recommend 
to pursue the here described findings in an immunocompetent tumor model. 




This procedure albeit is hindered by the highly restricted host range of measles 
viruses, which only allows replicative infections in primates and humans. 
Sequential infections illustrated a phenomenon called “viral competition”. The 
majority of double-infected cells was either infected by one or the other, but not 
by both virus constructs simultaneously. The Keyence microscope was applied 
to examine this finding in detail. Although most sequentially infected cells 
exhibited sole infection, some of them glowed yellow, which indicated 
coinfection by VACV and MeV-GFP. Further trials applying SRB assay and 
western blot ensured that “viral competition” did not limit the oncolytic potential 
of the combinatorial treatment regime. However, further studies should focus on 
the underlying mechanism of the here described phenomenon and its 













Onkolytische Viren wie beispielsweise Vaccinia- und Masernimpfviren sind 
lebende, sich selbst replizierende biologische Krebsmedikamente, die schon 
seit einigen Jahren zusammen mit etablierten Therapien eingesetzt werden 
(Bell, 2007). Während normales Gewerbe geschont wird, zerstören onkolytische 
Viren Krebszellen zielgerichtet durch Tumorlyse sowie durch die Etablierung 
einer wirtseigenen, gerichteten Immunreaktion gegen die malignen Zellen 
(Kaufman et al, 2015). Primäre Resistenzphänomene hochresistenter Tumor-
zellen verhindern zurzeit einen flächendeckenden Einsatz dieser neuen Thera-
peutika.  
Im Jahr 2010 präsentierten Le Boeuf et al. einen vielversprechenden Ansatz (Le 
Boeuf et al, 2010). Durch den kombinierten Einsatz von Vaccinia und Vesicular 
stomatitis Viren konnte ein Synergismus erreicht, und dadurch primäre 
Resistenzen überwunden werden (Le Boeuf et al, 2010). Masern- und Vaccinia-
viren haben bewiesen, dass sie nicht nur sicher sind, sondern in einigen Fällen 
auch äußerst effizient Tumorzellen bekämpfen.  
Auf der Grundlage hochresistenter menschlicher Tumorzellen haben wir in 
dieser Arbeit untersucht, ob Le Boeufs Erkenntnisse auf das Vacciniavirus GLV-
1h254 und das Masernimpfvirus MeV-GFP übertragbar sind. In 
Übereinstimmung mit den Forschern vermuteten wir, dass eine noch in Teilen 
bestehende Interferonantwort der Tumorzellen für das Auftreten primärer 
Virotherapie-Resistenzen verantwortlich sein könnte (Le Boeuf et al, 2010). Mit 
dem Einsatz des Vacciniavirus GLV-1h254 versuchten wir nun die gegen beide 
Viren gerichtete Immunreaktion zu unterbinden.  
Bevor mit den Doppelinfektionen begonnen werden konnte, war es nötig die für 
jede Tumorzelllinie passende Konzentration beider Viruskonstrukte zu 
bestimmen. Dabei fiel auf, dass jede Zelllinie unterschiedliche 
Auslegezellzahlen benötigte um Konfluenz zu erreichen, und mehr noch, dass 
dies sowohl das Überleben nicht infizierter Kontrollen als auch die 
Virusausbreitung beeinflusste.  




Nachdem die passenden Virusmengen bestimmt worden waren, untersuchten 
wir in Doppelinfektionsversuchen unterschiedliche Reihenfolgen und Zeitpunkte 
der Applikation der beiden Viruskonstrukte.  
Mit Hilfe des SRB Assays konnten wir die Überlegenheit eines kombinierten 
Verfahrens gegenüber Einzelinfektionen herausstellen. Doppelinfektionen mit 
Vaccinia als erstem Virus erzielten dabei die besten Ergebnisse, während der 
Zeitpunkt der Zweitinfektion die Resultate nur unwesentlich beeinflusste. 
Synergismus konnte dennoch nicht bestätigt werden, und auch die beob-
achteten additiven Effekte fielen nur gering aus.  
Naturgegeben ist unser in vitro-Setting nicht ausreichend um die komplexen 
Zusammenhänge zwischen onkolytischer Virotherapie und wirtseigener 
Immunreaktion zu bewerten. Wir empfehlen daher die hier erzielten Ergebnisse 
in einem immunkompetentem Tiermodel nachzuvollziehen. Zugegebenermaßen 
wird dieser Ansatz dadurch erschwert werden, dass Masernviren ausschließlich 
Primaten- und menschliche Zellen infizieren und sich in ihnen vermehren 
können. 
Während der Doppelinfektionsversuche beobachteten wir ein Phänomen, das 
wir „viralen Wettkampf“ tauften. Die Mehrzahl der doppelinfizierten Zellen war 
entweder vom ersten oder zweiten Viruskonstrukt infiziert, nicht jedoch von 
beiden gleichzeitig. Das Keyence Mikroskop half diese Beobachtung weiter zu 
verfolgen. Obwohl sich die meisten Zellen als einzelinfiziert zeigten, leuchteten 
einige wenige gelb auf und wurden somit als koinfiziert bewertet. Nachfolgende 
Analysen unter Verwendung des SRB Assays und Western Blot stellten sicher, 
dass der „virale Wettkampf“ nicht zu einer eingeschränkten Effektivität der 
Doppelinfektionen führte. Zukünftige Forschung sollte sich auf die zugrunde-
liegenden Mechanismen des hier beschriebenen Phänomens und ihr mögliches 
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